-- phpMyAdmin SQL Dump
-- version 4.4.15.9
-- https://www.phpmyadmin.net
--
-- Host: localhost
-- Generation Time: Jul 09, 2020 at 08:28 AM
-- Server version: 5.6.37
-- PHP Version: 5.6.31

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `pharma`
--

-- --------------------------------------------------------

--
-- Table structure for table `admin`
--

CREATE TABLE IF NOT EXISTS `admin` (
  `id` int(11) NOT NULL,
  `username` varchar(100) NOT NULL,
  `password` varchar(100) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `admin`
--

INSERT INTO `admin` (`id`, `username`, `password`, `createdate`) VALUES
(1, 'admin', 'admin', '2020-03-02 10:21:09');

-- --------------------------------------------------------

--
-- Table structure for table `ads_with_us`
--

CREATE TABLE IF NOT EXISTS `ads_with_us` (
  `id` int(11) NOT NULL,
  `name` varchar(100) NOT NULL,
  `email` varchar(50) NOT NULL,
  `phone` varchar(50) NOT NULL,
  `company` varchar(100) NOT NULL,
  `product` varchar(100) NOT NULL,
  `address` varchar(500) NOT NULL,
  `remark` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `ads_with_us`
--

INSERT INTO `ads_with_us` (`id`, `name`, `email`, `phone`, `company`, `product`, `address`, `remark`, `createdate`) VALUES
(1, 'Kajal MaheshBhai Sapariya', 'skajal1109@gmail.com', '7405592221', 'Left', 'sds', '', 'hhgvb', '2020-02-11 09:46:36');

-- --------------------------------------------------------

--
-- Table structure for table `blogs`
--

CREATE TABLE IF NOT EXISTS `blogs` (
  `id` int(11) NOT NULL,
  `title` varchar(255) NOT NULL,
  `short_description` varchar(255) NOT NULL,
  `description` longtext NOT NULL,
  `image` varchar(255) NOT NULL,
  `date` varchar(50) NOT NULL,
  `refrence_link` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=4 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `blogs`
--

INSERT INTO `blogs` (`id`, `title`, `short_description`, `description`, `image`, `date`, `refrence_link`, `createdate`) VALUES
(1, 'How Artificial Intelligence is adding value to the Healthcare sector', '', 'The word intelligence is derived from the Latin word intelligere, which means “to understand”. In general terms, it is related to “one’s ability to understand things” or “the capacity to acquire and apply knowledge and skills.</br></br>\r\nIntelligence can be broadly categorised into two forms, natural intelligence and artificial intelligence. Native or natural intelligence is also known as biological intelligence is organic in nature & confined to the human brain. Natural intelligence is a product of experience which can provide unique solutions and ideas for every new situation.  <br/>\r\nArtificial Intelligence or (machine intelligence) on the other hand, are high-end software-based programmes, commonly implemented in computer systems, robots, machines and specialized hardware etc. that can mimic human behaviour. The AI in practice today is derived from different fields of study like probability, mathematics, optimization & logic, computer science, psychology, control theory, information technology, operations research, linguistics and cognitive science etc. AI is an essential part of most of the technology-related fields & it is rapidly expanding to other industries and sectors. Artificial intelligence-based systems are tasks specific & only provide a set result for the predefined situation.<br/>\r\n<b>AI in the healthcare space</b>\r\nThe AI-based healthcare system can transform the industry through time-saving and cost-effective methods. AI has many applications in the field of medical science like patient engagement, predicting hospital readmission, treatment recommendation, diagnosis, accurate cancer detection, and in other administrative activities.<br/>\r\nThe AI can assist the doctor in finding the right treatment for the disease. The AI-based models are free from any biases & have a high speed of execution. There are various studies which suggested that there are many fields in healthcare where AI has outperformed human intelligence like in case of diagnosis. It is not wrong to say that the efficiency of lab testing is undoubtedly high and requires a shorter turnaround time with Artificial Intelligence. Medical images, such as X-ray, ultrasound, CT or MRI scan, are used vastly to diagnose a variety of diseases. \r\n', 'blog1.jpg', '', 'https://www.delveinsight.com/blog/', '2020-02-29 08:16:22'),
(2, 'Now, Artificial Intelligence to Accurately Identify Cancer Cells', '', 'In what could be regarded as a precursor to a new mode of cancer diagnosis, an artificial intelligence based tool, developed at the Osaka University in Japan, can precisely differentiate between different cancer cells, paving the way for automated determination of appropriate individualized cancer treatments.<br/>\r\nAs a matter of fact, there can be remarkable variation in the types of cancer cells among patients, even with the same cancer type. In view of the variation, it is necessary to identify the particular cell types for choosing the best treatment option. However, the current methods of doing so are time-consuming and often restricted by human error and limits of human sight.<br/>\r\nIn the new method involving artificial intelligence, the limitations of humans could be overcome by scanning the microscopic images of cancer cells and eliciting the nature of the cells with high accuracy than human judgment. In essence, the system is based on a convolutional neural network, a form of artificial intelligence modelled on the human visual system. During the studies, the artificial based system was applied to distinguish cancer cells in mice as well as humans.<br/>\r\nWe first trained our system on 8,000 images of cells obtained from a phase-contrast microscope,” one of the researchers said. “We then tested its accuracy on another 2,000 images, to see whether it had learned the features that distinguish mouse cancer cells from human ones, and radio-resistant cancer cells from radiosensitive ones,” the researcher further revealed.<br/>\r\n\r\n', 'blog3.jpg', '', 'https://www.delveinsight.com/blog/', '2020-02-29 08:16:29'),
(3, 'Japan has a new way to treate croneas', 'The Cornea– the outermost layer in the human eye, plays an important role in regulating the amount of light entering into the eye. It also protects the eye from germs, dust, and other harmful matter. Although this important part of the human body has a co', 'The Cornea– the outermost layer in the human eye, plays an important role in regulating the amount of light entering into the eye. It also protects the eye from germs, dust, and other harmful matter. Although this important part of the human body has a countless number of ways to get damaged. Corneal Abrasions, Dry eyes, Keratitis, Ocular herpes, corneal dystrophies, Keratoconus, etc. are some of the diseases that alter cornea terribly. These can also be destroyed by burns, trauma, or chemical radiations. At present, the corneas from donors are transplanted to the patients suffering from the diseased corneas. But there is always a chance of mismatching, autoimmune reactions, and unavailability of quality tissues.<br/>\r\nA Japanese committee lead by the Researchers at the Osaka University recently have proposed the idea to treat corneas that have been damaged, using Stem cell therapy. A sheet of tissues of induced pluripotent stem cells (IPSC) reprogrammed from donor cells into embryonic cells and then are transferred into the receiver. However, the theory is yet to be approved.<br/>\r\nThis isn’t a new domain for Japan. Japan has been proving its stronghold in stem cell and regenerative medicine research for long now. This could be due to the fact that Nobel Laureate Shinya Yamanaka who hailed from Japan invented Stem cell research.  Earlier a team studies the IPSC-based retinal pigmented epithelial cell therapy to treat macular degeneration which solely affects the retina. Opinion pieces and researches to use stem cell therapy to treat spinal cord injuries, Parkinson’s disease and Paralysis also exist.<br/>\r\nAlthough Japan is touching new heights in healthcare and regenerative medicine research but how will it manage to get rid of the stigma attached is one legitimate question.  ', 'Capture.png', '2020-03-04', 'https://www.delveinsight.com/blog/japan-has-got-new-ways-to-treat-corneas/', '2020-03-05 07:06:57');

-- --------------------------------------------------------

--
-- Table structure for table `case_studies`
--

CREATE TABLE IF NOT EXISTS `case_studies` (
  `id` int(11) NOT NULL,
  `title` varchar(100) NOT NULL,
  `short_description` varchar(255) NOT NULL,
  `description` longtext NOT NULL,
  `refrence_link` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `case_studies`
--

INSERT INTO `case_studies` (`id`, `title`, `short_description`, `description`, `refrence_link`, `createdate`) VALUES
(1, 'The Johnson & Johnson Tylenol Controversies', '', 'The case discusses the globalization efforts of Ranbaxy Laboratories (Ranbaxy), a leading pharma company in India. Ranbaxy started off distributing drugs in foreign countries and went on to play a major role in the global generics market. By 2004, the company had manufacturing plants in 10 locations, ground operations in 45 countries and its products were sold in 70 countries across the world. The case describes Ranbaxy''s foray in the US markets where it made a slow entry and adopted the route of Para IV filings to challenge the supremacy of big pharma companies. By the first quarter of 2005, Ranbaxy''s sales in the US decreased by US$ 25 million, which was attributed to severe price erosion in these markets due to increasing competition among the US generics. The case describes the challenges facing the company in the US and examines Ranbaxy''s growth strategy for the US markets.', 'https://www.icmrindia.org/casestudies/catalogue/Marketing/MKTG172.htm', '2020-02-29 08:18:39');

-- --------------------------------------------------------

--
-- Table structure for table `category`
--

CREATE TABLE IF NOT EXISTS `category` (
  `id` int(11) NOT NULL,
  `name` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=13 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `category`
--

INSERT INTO `category` (`id`, `name`, `createdate`) VALUES
(1, 'QS', '2020-02-29 05:50:07'),
(3, 'Production System', '2020-02-29 05:51:14'),
(4, 'Laboratory Control System', '2020-02-29 05:51:14'),
(5, 'Facilities and Equipment System', '2020-02-29 05:51:59'),
(6, 'Complaint Redressal Documents', '2020-02-29 05:51:59'),
(7, 'Employees', '2020-02-29 05:52:28'),
(8, 'Production & Control', '2020-02-29 05:52:28'),
(9, 'Data Maintenance', '2020-02-29 05:52:48'),
(10, 'Cleaning & Maintenance', '2020-02-29 05:52:48'),
(11, 'Materials System', '2020-06-30 11:33:24'),
(12, 'Packaging and Labeling system\r\n', '2020-07-01 06:02:11');

-- --------------------------------------------------------

--
-- Table structure for table `category_subcategory`
--

CREATE TABLE IF NOT EXISTS `category_subcategory` (
  `id` int(11) NOT NULL,
  `name` longtext NOT NULL,
  `category_id` int(11) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=88 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `category_subcategory`
--

INSERT INTO `category_subcategory` (`id`, `name`, `category_id`, `createdate`) VALUES
(18, 'Facilities and Equipment System - Inappropriate Design', 5, '2020-02-29 05:56:30'),
(29, 'Facilities & Equipment system - Cleaning validation\r\n', 5, '2020-06-30 06:41:35'),
(30, 'Facilities & Equipment system - Environmental monitoring\r\n', 5, '2020-06-30 07:08:11'),
(31, 'Laboratory Controls system - Procedural deficiencies\r\n', 4, '2020-06-30 07:13:24'),
(32, 'Laboratory Controls system - Procedural deficiencies\r\n', 4, '2020-06-30 07:17:52'),
(33, 'Facilities & Equipment system - Cross contamination\r\n', 5, '2020-06-30 07:30:16'),
(34, 'Quality system - Procedural deficiencies\r\n', 1, '2020-06-30 07:37:23'),
(35, 'Quality system - Quality unit inadequate\r\n', 1, '2020-06-30 07:48:53'),
(36, 'Facilities & Equipment system - Equipment qualification\r\n', 5, '2020-06-30 07:52:35'),
(37, 'Laboratory Controls system - Data integrity issues\r\n', 4, '2020-06-30 09:09:35'),
(38, 'Quality system - Investigations deficiencies\r\n', 1, '2020-06-30 09:16:31'),
(39, 'Facilities & Equipment system - Aseptic processing\n', 5, '2020-07-05 09:12:01'),
(40, 'Laboratory Controls system - Method validation\r\n', 4, '2020-06-30 10:35:21'),
(41, 'Quality system - Field Alert Report\r\n', 1, '2020-06-30 10:44:13'),
(42, 'Quality system - Process Validation\r\n', 1, '2020-06-30 10:59:17'),
(43, 'Quality system - Training\r\n', 1, '2020-06-30 11:06:09'),
(44, 'Laboratory Controls system - Computer system\r\n', 4, '2020-06-30 11:09:41'),
(45, 'Quality system - Complaints\r\n', 1, '2020-06-30 11:17:36'),
(46, 'Facilities & Equipment system - Facilities inadequacy\r\n', 5, '2020-06-30 11:25:18'),
(47, 'Materials system - Product storage\r\n', 11, '2020-06-30 11:34:08'),
(48, 'Production systems - Equipment maintenance\r\n', 3, '2020-06-30 11:42:31'),
(49, 'Laboratory Controls system - Product stability\r\n', 4, '2020-06-30 11:52:08'),
(50, 'Production systems - Media fills\r\n', 3, '2020-06-30 12:07:30'),
(51, 'Laboratory Controls system - Laboratory controls\r\n', 4, '2020-06-30 12:14:04'),
(52, 'Quality system - Data integrity issues\r\n', 1, '2020-06-30 13:07:58'),
(53, 'Materials system - Sampling\r\n', 11, '2020-06-30 13:10:42'),
(54, 'Quality system - Repeat observation\r\n', 1, '2020-06-30 13:14:26'),
(55, 'Quality system - Product Quality Review\r\n', 1, '2020-06-30 13:19:40'),
(56, 'Quality system - Reserve sample\r\n', 1, '2020-07-01 05:52:23'),
(57, 'Production systems - Quality unit inadequate\r\n', 3, '2020-07-01 05:57:53'),
(58, 'Packaging and Labeling system - Inadequate Labeling Specification', 12, '2020-07-01 06:02:50'),
(59, 'Facilities & Equipment system - Repeat observation\r\n', 5, '2020-07-01 06:13:39'),
(60, 'Packaging and Labeling system - Extractable and Leachable studies\r\n', 12, '2020-07-01 06:23:22'),
(61, 'Facilities & Equipment system - Equipment maintenance\r\n', 5, '2020-07-01 06:40:03'),
(62, 'Facilities & Equipment system - Pest Control\r\n', 5, '2020-07-01 06:51:06'),
(63, 'Quality system - Computer system\r\n', 1, '2020-07-01 07:05:54'),
(64, 'Laboratory Controls system - OOS\r\n', 4, '2020-07-01 07:34:38'),
(65, 'Production systems - Hold Time Study\r\n', 3, '2020-07-01 08:13:46'),
(66, 'Facilities & Equipment system - Computer system\r\n', 5, '2020-07-01 08:51:51'),
(67, 'Production System - Investigations deficiencies\r\n', 3, '2020-07-01 09:24:08'),
(68, 'Laboratory Controls system - Change management\r\n', 4, '2020-07-01 11:10:37'),
(69, 'Facilities & Equipment system - Laboratory controls\r\n', 5, '2020-07-01 12:27:32'),
(70, 'Laboratory Controls system - Microbiological\r\n', 4, '2020-07-01 12:51:49'),
(71, 'Production System - Procedural deficiencies\r\n', 3, '2020-07-02 05:29:26'),
(72, 'Quality system - Cleaning validation\r\n', 1, '2020-07-02 05:33:25'),
(73, 'Quality system - FAR\r\n', 1, '2020-07-02 06:20:22'),
(74, 'Facilities & Equipment system - Contamination\r\n', 5, '2020-07-02 06:25:48'),
(75, 'Materials system - Equipment qualification\r\n', 11, '2020-07-02 13:18:48'),
(76, 'Materials system - Facilities inadequacy\r\n', 11, '2020-07-02 13:21:40'),
(77, 'Quality system - CAPA inadequcies\r\n', 1, '2020-07-02 17:29:12'),
(78, 'Facilities & Equipment system - Smoke studies\r\n', 5, '2020-07-03 06:01:01'),
(79, 'Quality system - Suppliers\r\n', 1, '2020-07-03 07:53:11'),
(80, 'Production systems - Aseptic processing\n', 3, '2020-07-05 09:12:50'),
(81, 'Quality system - Process monitoring\r\n', 1, '2020-07-03 09:42:14'),
(82, 'Quality system - Product stability\r\n', 1, '2020-07-03 09:55:54'),
(83, 'Quality system - OOS\r\n', 1, '2020-07-03 11:46:02'),
(84, 'Quality system - Document control\r\n', 1, '2020-07-04 18:28:54'),
(85, 'Facilities & Equipment system - Cleaning and maintenanace\r\n', 5, '2020-07-04 18:33:36'),
(86, 'Quality system - Change management\r\n', 1, '2020-07-04 18:43:35'),
(87, 'Facilities & Equipment system - Calibration\r\n', 5, '2020-07-04 18:50:33');

-- --------------------------------------------------------

--
-- Table structure for table `company`
--

CREATE TABLE IF NOT EXISTS `company` (
  `id` int(11) NOT NULL,
  `company_name` varchar(1000) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=42 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `company`
--

INSERT INTO `company` (`id`, `company_name`, `createdate`) VALUES
(1, 'Lupin - Salcette Goa', '2020-02-07 06:10:10'),
(2, 'Dr Reddy - Telangana', '2020-02-07 06:10:10'),
(3, 'Lupin - Pithampur', '2020-02-07 06:10:43'),
(4, 'Indoco Remedies - Goa', '2020-02-07 06:10:43'),
(5, 'Shilpa Medi - Raichur Karnatak', '2020-02-07 06:10:50'),
(6, 'Dr Reddy - Bollaram AP', '2020-03-07 11:44:45'),
(7, 'Cipla - Bangalore', '2020-03-07 11:44:45'),
(8, 'Dr Reddy - Visakhapatnam', '2020-03-07 11:45:06'),
(9, 'Aurobindo Pharma -Medchal Telangana', '2020-03-07 11:45:06'),
(10, 'Lupin - Aurangabad', '2020-03-07 11:45:23'),
(11, 'Cadila - Ahmedabad', '2020-03-07 11:45:23'),
(12, 'Torrent Pharma - Indrad', '2020-03-07 11:45:45'),
(13, 'Aurobindo Pharma - Mahabubnagar', '2020-03-07 11:45:45'),
(14, 'Sun Pharma Med - Halol', '2020-03-13 13:39:46'),
(15, 'Biocon - Bangalore', '2020-03-13 13:39:46'),
(16, 'Dr Reddy - Ranasthalam AP', '2020-03-13 13:40:41'),
(17, 'Sun Pharma - Halol', '2020-03-13 13:40:41'),
(18, 'Aurobindo Pharma - Jinnaram Telangana', '2020-03-13 13:42:20'),
(19, 'Aurobindo Pharma - Pashamylaram Telangana', '2020-03-13 13:42:20'),
(20, 'Cipla - Goa', '2020-03-13 13:43:06'),
(21, 'Aurobindo Pharma - Polepally Telangana', '2020-03-13 13:43:06'),
(22, 'Lupin - Tarapur', '2020-03-13 13:43:27'),
(23, 'Ipca - Silvasa', '2020-03-13 13:43:27'),
(24, 'Dr Reddy - Duvvada', '2020-03-13 13:43:50'),
(25, 'Biocon - Bangalore', '2020-03-13 13:43:50'),
(26, 'Hospira Healthcare - Sriperumbudur TN', '2020-03-13 13:44:42'),
(27, 'Auronext - Bhiwadi Rajasthan', '2020-03-13 13:44:42'),
(28, 'Dr Reddy - Medak Telengana', '2020-03-13 13:44:59'),
(29, 'cipla - Pithampur', '2020-03-13 13:44:59'),
(30, 'Suven Life - Telengana', '2020-03-13 13:45:35'),
(31, 'Shilpa Medi - Raichur Karnatak', '2020-03-13 13:45:35'),
(32, 'Aurobindo Pharma - Medak Hyderabad', '2020-03-13 13:46:35'),
(33, 'Alembic - Tajpura', '2020-03-13 13:46:35'),
(34, 'Galaxy Surfactants Limited\r\n', '2020-07-01 08:29:29'),
(35, 'Glenmark - Pithampur\r\n', '2020-07-01 08:41:21'),
(36, 'Alkem - Daman\r\n', '2020-07-01 09:56:34'),
(37, 'Galaxy Surfactants - Tarapur 2\r\n', '2020-07-01 10:07:49'),
(38, 'Hetero Drugs - Mandal Telengana\r\n', '2020-07-01 11:37:00'),
(39, 'Unichem - Pithampur\r\n', '2020-07-01 12:41:52'),
(40, 'Liva Pharma - Vadodara\r\n', '2020-07-01 12:58:28'),
(41, 'Dishman Carbogen - Ahmedabad\r\n', '2020-07-02 05:57:19');

-- --------------------------------------------------------

--
-- Table structure for table `current_affairs`
--

CREATE TABLE IF NOT EXISTS `current_affairs` (
  `id` int(11) NOT NULL,
  `title` varchar(255) NOT NULL,
  `short_description` varchar(255) NOT NULL,
  `description` longtext NOT NULL,
  `image` varchar(255) NOT NULL,
  `date` date NOT NULL,
  `refrence_link` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `current_affairs`
--

INSERT INTO `current_affairs` (`id`, `title`, `short_description`, `description`, `image`, `date`, `refrence_link`, `createdate`) VALUES
(1, 'Exports of certain APIs, formulations put under restricted category amid coronavirus outbreak', 'Paracetamol, Tinidazole, Metronidaxole, Vitamins B1, B6, B 12 included in the list.\n', 'India today restricted export of about 26 Active Pharmaceutical Ingredients (APIs) and formulations including antibiotics, vitamins and hormones- with immediate effect, as the government explores measures to ensure there is no shortage of drugs in India due to the lockdown in China’s Hubei’s province, the epicentre of the Coronavirus outbreak and also a major source of raw material or APIs.<br/>\nAccording to the notification dated March 3, the Directorate General of Foreign trade (DGFT) restricted export of APIs and formulations like Paracetamol, Tinidazole, Metronidaxole, Vitamins B1, B6, B 12, hormone progesterone, formulations made of Chromaphenicol, formulations made of Ornidazole, among others.<br/>\nThe decision has been taken following a recommendation by high level committee formed by the Department of Pharmaceuticals (DoP). ET had first reported about that the committee was contemplating restrictions on exports so as to curb any shortages in India.\n', 'pharma-getty.webp', '2020-03-03', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 10:38:37'),
(2, 'Coronavirus medicine: An arthritis drug could be the answer everyone is looking for', 'The Chinese government approved Swiss drugmaker Roche''s anti-inflammation drug Actemra to treat severe coronavirus symptoms. This comes at a time when countries around the world desperately search for new ways to combat the deadly infection.', 'A decade-old drug used to treat inflammation in arthritis patients could be the answer to the world''s fears of the coronavirus.<br/>\r\nActemra, an anti-inflammation drug made by Swiss drugmaker Roche, has been approved by the Chinese government to treat severe coronavirus symptoms. This comes at a time when countries around the world are desperately searching for ways to combat the deadly infection.<br/>\r\nThe Swiss drug maker donated nearly $2 million worth of Actemra to China, its local operations said in a blog post on Monday.<br/>\r\nAccording to reports, 14 serious and critically ill patients treated with existing medicines at a hospital affiliated with the University of Science and Technology of China (USTC) showed positive results.\r\n', 'coronavirus.webp', '2020-03-05', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/', '2020-03-05 10:45:22');

-- --------------------------------------------------------

--
-- Table structure for table `form483`
--

CREATE TABLE IF NOT EXISTS `form483` (
  `id` int(11) NOT NULL,
  `file_name` varchar(255) NOT NULL,
  `pdf_name` varchar(255) NOT NULL,
  `company_name` int(11) NOT NULL,
  `date` date NOT NULL,
  `year` varchar(100) NOT NULL,
  `category` int(11) NOT NULL,
  `category_sub` int(10) NOT NULL,
  `inspector` varchar(20) NOT NULL,
  `observation` int(10) NOT NULL,
  `fei` varchar(100) NOT NULL,
  `firm_name` varchar(255) NOT NULL,
  `address` varchar(1000) NOT NULL,
  `location` varchar(1000) NOT NULL,
  `name_title` varchar(1000) NOT NULL,
  `date_of_inspection` varchar(255) NOT NULL,
  `type_of_es` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=541 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `form483`
--

INSERT INTO `form483` (`id`, `file_name`, `pdf_name`, `company_name`, `date`, `year`, `category`, `category_sub`, `inspector`, `observation`, `fei`, `firm_name`, `address`, `location`, `name_title`, `date_of_inspection`, `type_of_es`, `createdate`) VALUES
(188, 'Biocon_05012018_O-1.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 5, 29, '41,42', 1, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', 'Drug Manufacturer', '2020-07-06 09:22:30'),
(189, 'Biocon_05012018_O-2.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 5, 30, '41,42', 2, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', 'Drug Manufacturer', '2020-07-06 09:22:41'),
(190, 'Biocon_05012018_O-3.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 4, 31, '41,42', 3, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', 'Drug Manufacturer', '2020-07-06 09:22:59'),
(191, 'Biocon_05012018_O-4.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 5, 33, '41,42', 4, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', '04/23/2018 - 05/01/2018', '2020-07-06 09:23:05'),
(192, 'Biocon_05012018_O-5.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 1, 34, '41,42', 5, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', 'Drug Manufacturer', '2020-07-06 09:27:19'),
(193, 'Biocon_05012018_O-6.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 1, 35, '41,42', 6, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', 'Drug Manufacturer', '2020-07-06 09:27:27'),
(194, 'Biocon_05012018_O-7.png', 'Biocon_05012018_O-A.pdf', 15, '2018-05-01', '2018', 5, 36, '41,42', 7, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Shreehas P. Tambe, COO\r\n', '04/23/2018 - 05/01/2018', 'Drug Manufacturer', '2020-07-06 09:27:39'),
(195, 'Hospira Healthcare_04032018_O-1.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 1, 35, '21,43', 1, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 09:40:45'),
(196, 'Hospira Healthcare_04032018_O-2.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 4, 37, '21,43', 2, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 09:40:50'),
(197, 'Hospira Healthcare_04032018_O-3.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 4, 37, '21,43', 3, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 09:41:03'),
(198, 'Hospira Healthcare_04032018_O-4.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 1, 38, '21,43', 4, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 09:41:11'),
(199, 'Hospira Healthcare_04032018_O-5.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 1, 38, '21,43', 5, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 09:41:20'),
(200, 'Hospira Healthcare_04032018_O-6.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 1, 35, '21,43', 6, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 09:41:27'),
(201, 'Hospira Healthcare_04032018_O-8.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 5, 39, '21,43', 8, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-08 13:05:17'),
(202, 'Hospira Healthcare_04032018_O-9.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 4, 40, '21,43', 9, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-08 13:05:23'),
(203, 'Hospira Healthcare_04032018_O-10.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 5, 36, '21,43', 10, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-08 13:05:28'),
(204, 'Hospira Healthcare_04032018_O-11.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 1, 41, '21,43', 11, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-08 13:05:35'),
(205, 'Auronext_03062018_O-1.png', 'Auronext_03062018_O-A.pdf', 27, '2018-03-06', '2018', 1, 42, '44,45', 1, '3009883410', 'Auronext Pharma', 'A - 1128, Riico Ind. Area\r\n', 'Bhiwadi, Rajasthan, 301019, India\r\n', 'Mr. NavinKumar Jain, Plant Head\r\n', '02/26/2018 - 03/06/2019', 'Drug Manufacturer', '2020-07-08 13:05:39'),
(206, 'Auronext_03062018_O-2.png', 'Auronext_03062018_O-A.pdf', 27, '2018-03-06', '2018', 1, 43, '44,45', 2, '3009883410', 'Auronext Pharma', 'A - 1128, Riico Ind. Area\r\n', 'Bhiwadi, Rajasthan, 301019, India\r\n', 'Mr. NavinKumar Jain, Plant Head\r\n', '02/26/2018 - 03/06/2019', 'Drug Manufacturer', '2020-07-08 13:05:44'),
(207, 'Auronext_03062018_O-3.png', 'Auronext_03062018_O-A.pdf', 27, '2018-03-06', '2018', 4, 44, '44,45', 3, '3009883410', 'Auronext Pharma', 'A - 1128, Riico Ind. Area\r\n', 'Bhiwadi, Rajasthan, 301019, India\r\n', 'Mr. NavinKumar Jain, Plant Head\r\n', '02/26/2018 - 03/06/2019', 'Drug Manufacturer', '2020-07-08 13:05:50'),
(208, 'Dr. Reddy_03092018_O-1.png', 'Dr. Reddy_03092018_O-A.pdf', 28, '2018-03-09', '2018', 1, 35, '8', 1, '3003184497', 'Dr. Reddy''s Lab. Ltd. (Chem Tech Ops III)', 'Plot 116, Bollaram\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Dr. Sunil Bawane, Sen. Director & Site Head Mfg.\r\n', '03/05/2018 - 03/09/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-06-30 11:15:45'),
(209, 'Dr. Reddy_03092018_O-2.png', 'Dr. Reddy_03092018_O-A.pdf', 28, '2018-03-09', '2018', 1, 45, '8', 2, '3003184497', 'Dr. Reddy''s Lab. Ltd. (Chem Tech Ops III)', 'Plot 116, Bollaram\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Dr. Sunil Bawane, Sen. Director & Site Head Mfg.\r\n', '03/05/2018 - 03/09/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-06-30 11:22:46'),
(210, 'Dr. Reddy_03092018_O-3.png', 'Dr. Reddy_03092018_O-A.pdf', 28, '2018-03-09', '2018', 5, 46, '8', 3, '3003184497', 'Dr. Reddy''s Lab. Ltd. (Chem Tech Ops III)', 'Plot 116, Bollaram\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Dr. Sunil Bawane, Sen. Director & Site Head Mfg.\r\n', '03/05/2018 - 03/09/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-02 06:49:33'),
(211, 'Dr. Reddy_03092018_O-4.png', 'Dr. Reddy_03092018_O-A.pdf', 28, '2018-03-09', '2018', 11, 47, '8', 4, '3003184497', 'Dr. Reddy''s Lab. Ltd. (Chem Tech Ops III)', 'Plot 116, Bollaram\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Dr. Sunil Bawane, Sen. Director & Site Head Mfg.\r\n', '03/05/2018 - 03/09/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-06-30 11:36:29'),
(212, 'Dr. Reddy_03092018_O-5.png', 'Dr. Reddy_03092018_O-A.pdf', 28, '2018-03-09', '2018', 3, 48, '8', 5, '3003184497', 'Dr. Reddy''s Lab. Ltd. (Chem Tech Ops III)', 'Plot 116, Bollaram\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Dr. Sunil Bawane, Sen. Director & Site Head Mfg.\r\n', '03/05/2018 - 03/09/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-06-30 11:44:31'),
(213, 'Cipla-Pithampur_04132018-2019_All-All_O-1.png', 'Cipla-Pithampur_04132018-2019_All-All_O-A.pdf', 29, '2018-04-13', '2018', 4, 49, '46', 1, '3008581988', 'Cipla Limited', 'Plot 9 & 10, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Aashish Zitshi, Sen. Director & Sen. Head\r\n', '04/02/2018 - 04/13/2018', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-06-30 12:03:35'),
(214, 'Cipla-Pithampur_04132018-2019_All-All_O-2.png', 'Cipla-Pithampur_04132018-2019_All-All_O-A.pdf', 29, '2018-04-13', '2018', 3, 50, '46', 2, '3008581988', 'Cipla Limited', 'Plot 9 & 10, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Aashish Zitshi, Sen. Director & Sen. Head\r\n', '04/02/2018 - 04/13/2018', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-06-30 12:09:16'),
(215, 'Cipla-Pithampur_04132018-2019_All-All_O-3.png', 'Cipla-Pithampur_04132018-2019_All-All_O-A.pdf', 29, '2018-04-13', '2018', 4, 51, '46', 3, '3008581988', 'Cipla Limited', 'Plot 9 & 10, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Aashish Zitshi, Sen. Director & Sen. Head\r\n', '04/02/2018 - 04/13/2018', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-06-30 12:16:21'),
(216, 'Suven Life_02152018_O-1.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 4, 51, '31', 1, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:04:04'),
(217, 'Suven Life_02152018_O-2.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 5, 29, '31', 2, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:06:13'),
(218, 'Suven Life_02152018_O-3.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 1, 52, '31', 3, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:09:41'),
(219, 'Suven Life_02152018_O-4.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 11, 53, '31', 4, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:13:14'),
(220, 'Suven Life_02152018_O-5.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 1, 54, '31', 5, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:16:17'),
(221, 'Suven Life_02152018_O-6.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 1, 54, '31', 6, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:18:05'),
(222, 'Suven Life_02152018_O-7.png', 'Suven Life_02152018_O-A.pdf', 30, '2018-02-15', '2018', 1, 55, '31', 7, '1000623515', 'Suven Life Sciences Limited', 'Plot 262-271, IDA Pashamylaram\r\n', 'Telengana, 502307, India\r\n', 'Mr. Venkat Jasti, Chairman & CEO\r\n', '02/05/2018 - 02/15/2018', 'Drug Manufacturer', '2020-06-30 13:21:11'),
(223, 'Indoco_01192018_O-1.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 4, 37, '4', 1, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 05:44:41'),
(224, 'Indoco_01192018_O-2.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 4, 51, '4', 2, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 05:47:54'),
(225, 'Indoco_01192018_O-3.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 4, 49, '4', 3, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 05:49:45'),
(226, 'Indoco_01192018_O-4.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 1, 56, '4', 4, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 05:54:09'),
(227, 'Indoco_01192018_O-5.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 1, 34, '4', 5, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 05:56:29'),
(228, 'Indoco_01192018_O-6.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 3, 57, '4', 6, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 06:01:09'),
(229, 'Indoco_01192018_O-7.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 12, 58, '4', 7, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 06:04:19'),
(230, 'Indoco_01192018_O-8.png', 'Indoco_01192018_O-A.pdf', 4, '2018-01-19', '2018', 5, 18, '4', 8, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajendra Potabatti, GM Production\r\n', '01/15/2018 - 01/19/2018', 'Tablet Manufacturer', '2020-07-01 06:06:00'),
(231, 'Shilpa Medicare_01192018_O-1.png', 'Shilpa Medicare_01192018_O-A.pdf', 5, '2018-01-19', '2018', 5, 59, '31', 1, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. V K Shrawat, COO\r\n', '01/16/2018 - 01/19/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-01 06:16:42'),
(232, 'Shilpa Medicare_01192018_O-2.png', 'Shilpa Medicare_01192018_O-A.pdf', 5, '2018-01-19', '2018', 5, 30, '31', 2, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. V K Shrawat, COO\r\n', '01/16/2018 - 01/19/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-01 06:18:54'),
(233, 'Shilpa Medicare_01192018_O-3.png', 'Shilpa Medicare_01192018_O-A.pdf', 5, '2018-01-19', '2018', 12, 60, '31', 3, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. V K Shrawat, COO\r\n', '01/16/2018 - 01/19/2018', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-01 06:25:16'),
(234, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-1.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 5, 61, '47', 1, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 06:42:38'),
(235, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-2.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 5, 61, '47', 2, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 06:47:51'),
(236, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-3.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 5, 36, '47', 3, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 06:50:10'),
(237, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-4.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 5, 62, '47', 4, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 06:55:53'),
(238, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-5.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 1, 34, '47', 5, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 06:58:43'),
(239, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-6.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 1, 43, '47', 6, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 07:00:43'),
(240, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-7.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 1, 34, '47', 7, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 07:02:38'),
(241, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-8.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 4, 51, '47', 8, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 07:04:18'),
(242, 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-9.png', 'Aurobindo-MedakHyderabad_02202018-2019_All-All_O-A.pdf', 32, '2018-02-20', '2018', 1, 63, '47', 9, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, AVP - QA/QC\r\n', '02/12/2018 - 02/20/2018', 'Drug Manufacturer', '2020-07-01 07:07:23'),
(243, 'Alembic_03202018_O-1.png', 'Alembic_03202018_O-A.pdf', 33, '2018-03-20', '2018', 4, 64, '48', 1, '3004956904', 'Alembic Pharmaceuticals Limited', 'Panelav, Baska\r\n', 'Tajpura, Gujarat, 389350, India\r\n', 'Mr. Ravindra K. Pandey, Head of Formulation Operations\r\n', '03/12/2018 - 03/20/2018', 'Drug Manufacturer', '2020-07-01 07:59:56'),
(244, 'Alembic_03202018_O-2.png', 'Alembic_03202018_O-A.pdf', 33, '2018-03-20', '2018', 1, 43, '48', 2, '3004956904', 'Alembic Pharmaceuticals Limited', 'Panelav, Baska\r\n', 'Tajpura, Gujarat, 389350, India\r\n', 'Mr. Ravindra K. Pandey, Head of Formulation Operations\r\n', '03/12/2018 - 03/20/2018', 'Drug Manufacturer', '2020-07-01 08:12:31'),
(245, 'Alembic_03202018_O-3.png', 'Alembic_03202018_O-A.pdf', 33, '2018-03-20', '2018', 3, 65, '48', 3, '3004956904', 'Alembic Pharmaceuticals Limited', 'Panelav, Baska\r\n', 'Tajpura, Gujarat, 389350, India\r\n', 'Mr. Ravindra K. Pandey, Head of Formulation Operations\r\n', '03/12/2018 - 03/20/2018', 'Drug Manufacturer', '2020-07-01 08:15:28'),
(246, 'Sun Pharma_02232018_O-1.png', 'Sun Pharma_02232018_O-A.pdf', 17, '2018-02-23', '2018', 5, 46, '26,49,50', 1, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '02/12/2018 - 02/23/2018', 'Drug Manufacturer', '2020-07-08 13:06:34'),
(247, 'Sun Pharma_02232018_O-2.png', 'Sun Pharma_02232018_O-A.pdf', 17, '2018-02-23', '2018', 5, 61, '26,49,50', 2, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '02/12/2018 - 02/23/2018', 'Drug Manufacturer', '2020-07-08 13:06:44'),
(248, 'Sun Pharma_02232018_O-3.png', 'Sun Pharma_02232018_O-A.pdf', 17, '2018-02-23', '2018', 1, 34, '26,49,50', 3, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '02/12/2018 - 02/23/2018', 'Drug Manufacturer', '2020-07-08 13:06:53'),
(249, 'Galaxy Surfactants_03232018_O-1.png', 'Galaxy Surfactants_03232018_O-A.pdf', 34, '2018-03-23', '2018', 1, 43, '33', 1, '3010166890', 'Galaxy Surfactants Limited', 'Plot - 3, M - 3, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Unnathan Shekhar, MD\r\n', '03/19/2018 - 03/23/2018', 'Drug Manufacturer', '2020-07-01 08:31:54'),
(250, 'Galaxy Surfactants_03232018_O-2.png', 'Galaxy Surfactants_03232018_O-A.pdf', 34, '2018-03-23', '2018', 4, 40, '33', 2, '3010166890', 'Galaxy Surfactants Limited', 'Plot - 3, M - 3, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Unnathan Shekhar, MD\r\n', '03/19/2018 - 03/23/2018', 'Drug Manufacturer', '2020-07-01 08:34:43'),
(251, 'Galaxy Surfactants_03232018_O-3.png', 'Galaxy Surfactants_03232018_O-A.pdf', 34, '2018-03-23', '2018', 4, 49, '33', 3, '3010166890', 'Galaxy Surfactants Limited', 'Plot - 3, M - 3, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Unnathan Shekhar, MD\r\n', '03/19/2018 - 03/23/2018', 'Drug Manufacturer', '2020-07-01 08:37:16'),
(252, 'Galaxy Surfactants_03232018_O-4.png', 'Galaxy Surfactants_03232018_O-A.pdf', 34, '2018-03-23', '2018', 1, 55, '33', 4, '3010166890', 'Galaxy Surfactants Limited', 'Plot - 3, M - 3, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Unnathan Shekhar, MD\r\n', '03/19/2018 - 03/23/2018', 'Drug Manufacturer', '2020-07-01 08:39:11'),
(253, 'Glenmark_05242018_O-1.png', 'Glenmark_05242018_O-A.pdf', 35, '2018-05-24', '2018', 4, 40, '14,36', 1, '3008565058', 'Glenmark Pharmaceuticals Ltd.', 'Plot 2, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Darshan Makhey, President - Global Quality\r\n', '05/14/2018 - 05/24/2018', 'Finished Drugs Manufacturer', '2020-07-08 13:07:01'),
(254, 'Glenmark_05242018_O-2.png', 'Glenmark_05242018_O-A.pdf', 35, '2018-05-24', '2018', 4, 31, '14,36', 2, '3008565058', 'Glenmark Pharmaceuticals Ltd.', 'Plot 2, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Darshan Makhey, President - Global Quality\r\n', '05/14/2018 - 05/24/2018', 'Finished Drugs Manufacturer', '2020-07-08 13:07:05'),
(255, 'Glenmark_05242018_O-3.png', 'Glenmark_05242018_O-A.pdf', 35, '2018-05-24', '2018', 1, 38, '14,36', 3, '3008565058', 'Glenmark Pharmaceuticals Ltd.', 'Plot 2, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Darshan Makhey, President - Global Quality\r\n', '05/14/2018 - 05/24/2018', 'Finished Drugs Manufacturer', '2020-07-08 13:07:10'),
(256, 'Glenmark_05242018_O-4.png', 'Glenmark_05242018_O-A.pdf', 35, '2018-05-24', '2018', 5, 66, '14,36', 4, '3008565058', 'Glenmark Pharmaceuticals Ltd.', 'Plot 2, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Darshan Makhey, President - Global Quality\r\n', '05/14/2018 - 05/24/2018', 'Finished Drugs Manufacturer', '2020-07-08 13:07:14'),
(257, 'Glenmark_05242018_O-5.png', 'Glenmark_05242018_O-A.pdf', 35, '2018-05-24', '2018', 1, 35, '14,36', 5, '3008565058', 'Glenmark Pharmaceuticals Ltd.', 'Plot 2, Pharma Zone, SEZ\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Darshan Makhey, President - Global Quality\r\n', '05/14/2018 - 05/24/2018', 'Finished Drugs Manufacturer', '2020-07-08 13:07:19'),
(258, 'Cipla-Salcette_01252018-2019_All-All_O-1.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 3, 67, '4', 1, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:27:19'),
(259, 'Cipla-Salcette_01252018-2019_All-All_O-2.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 1, 34, '4', 2, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:35:44'),
(260, 'Cipla-Salcette_01252018-2019_All-All_O-3.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 4, 51, '4', 3, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:39:29'),
(261, 'Cipla-Salcette_01252018-2019_All-All_O-4.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 4, 64, '4', 4, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:40:59'),
(262, 'Cipla-Salcette_01252018-2019_All-All_O-5.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 1, 56, '4', 5, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:44:17'),
(263, 'Cipla-Salcette_01252018-2019_All-All_O-6.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 4, 51, '4', 6, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:46:11'),
(264, 'Cipla-Salcette_01252018-2019_All-All_O-7.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 1, 35, '4', 7, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:49:41'),
(265, 'Cipla-Salcette_01252018-2019_All-All_O-8.png', 'Cipla-Salcette_01252018-2019_All-All_O-A.pdf', 20, '2018-01-25', '2018', 5, 36, '4', 8, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Tapas Datta, SVP\r\n', '01/22/2018 - 01/25/2018', 'Pharmaceutical Manufacturer', '2020-07-01 09:54:33'),
(266, 'Galaxy Surfactants_03302018_O-1.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 1, 35, '33', 1, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:10:42'),
(267, 'Galaxy Surfactants_03302018_O-2.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 4, 40, '33', 2, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:12:52'),
(268, 'Galaxy Surfactants_03302018_O-3.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 4, 49, '33', 3, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:17:09'),
(269, 'Galaxy Surfactants_03302018_O-4.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 1, 43, '33', 4, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:19:54'),
(270, 'Galaxy Surfactants_03302018_O-5.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 5, 29, '33', 5, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:21:55'),
(271, 'Galaxy Surfactants_03302018_O-6.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 5, 36, '33', 6, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:23:44'),
(272, 'Galaxy Surfactants_03302018_O-7.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 1, 38, '33', 7, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:36:57'),
(273, 'Galaxy Surfactants_03302018_O-8.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 1, 34, '33', 8, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:44:06'),
(274, 'Galaxy Surfactants_03302018_O-9.png', 'Galaxy Surfactants_03302018_O-A.pdf', 37, '2018-03-30', '2018', 1, 55, '33', 9, '3004879807', 'Galaxy Surfactants Limited', 'Plot - N46, MIDC Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr. Milind Patil, GM\r\n', '03/26/2018 - 03/30/2018', 'Drug Manufacturer', '2020-07-01 10:55:02'),
(275, 'Alkem_03272018_O-1.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 1, 35, '26,31,51', 1, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:07:47'),
(276, 'Alkem_03272018_O-2.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 1, 35, '26,31,51', 2, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:07:51'),
(277, 'Alkem_03272018_O-3.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 4, 51, '26,31,51', 3, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:07:55'),
(278, 'Alkem_03272018_O-4.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 1, 35, '26,31,51', 4, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:00'),
(279, 'Alkem_03272018_O-5.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 4, 68, '26,31,51', 5, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:04'),
(280, 'Alkem_03272018_O-6.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 4, 51, '26,31,51', 6, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:09'),
(281, 'Alkem_03272018_O-7.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 1, 52, '26,31,51', 7, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:13'),
(282, 'Alkem_03272018_O-8.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 1, 38, '26,31,51', 8, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:17'),
(283, 'Alkem_03272018_O-9.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 5, 66, '26,31,51', 9, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:20'),
(284, 'Alkem_03272018_O-10.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 4, 51, '26,31,51', 10, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:23'),
(285, 'Alkem_03272018_O-11.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 4, 51, '26,31,51', 11, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:28'),
(286, 'Alkem_03272018_O-12.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 5, 46, '26,31,51', 12, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:33'),
(287, 'Alkem_03272018_O-13.png', 'Alkem_03272018_O-A.pdf', 36, '2018-03-27', '2018', 1, 43, '26,31,51', 13, '3006370524', 'Alkem Laboratories Limited', '167 MGUN road\r\n', 'Daman, 396210, India\r\n', 'Mr. Adil D. Billimoria, President - Quality & Compliance\r\n', '03/19/2018 - 03/27/2018', 'Drug Manufacturer', '2020-07-08 13:08:36'),
(288, 'HeteroDrugs_03022018_O-1.png', 'Hetero Drugs_03022018_O-A.pdf', 38, '2018-03-02', '2018', 4, 64, '8', 1, '3003510514', 'Hetero Drugs Limited', 'Plot 213, Bonthapally Village\r\n', 'Mandal, Telengana, 502313, India\r\n', 'Mr. J Sambi Reddy, Director Ops\r\n', '02/26/2018 - 03/02/2018', 'Drug Manufacturer', '2020-07-04 18:56:05'),
(289, 'HeteroDrugs_03022018_O-2.png', 'Hetero Drugs_03022018_O-A.pdf', 38, '2018-03-02', '2018', 4, 44, '8', 2, '3003510514', 'Hetero Drugs Limited', 'Plot 213, Bonthapally Village\r\n', 'Mandal, Telengana, 502313, India\r\n', 'Mr. J Sambi Reddy, Director Ops\r\n', '02/26/2018 - 03/02/2018', 'Drug Manufacturer', '2020-07-04 18:58:16'),
(290, 'HeteroDrugs_03022018_O-3.png', 'Hetero Drugs_03022018_O-A.pdf', 38, '2018-03-02', '2018', 1, 43, '8', 3, '3003510514', 'Hetero Drugs Limited', 'Plot 213, Bonthapally Village\r\n', 'Mandal, Telengana, 502313, India\r\n', 'Mr. J Sambi Reddy, Director Ops\r\n', '02/26/2018 - 03/02/2018', 'Drug Manufacturer', '2020-07-04 18:58:34'),
(291, 'HeteroDrugs_03022018_O-4.png', 'Hetero Drugs_03022018_O-A.pdf', 38, '2018-03-02', '2018', 5, 61, '8', 4, '3003510514', 'Hetero Drugs Limited', 'Plot 213, Bonthapally Village\r\n', 'Mandal, Telengana, 502313, India\r\n', 'Mr. J Sambi Reddy, Director Ops\r\n', '02/26/2018 - 03/02/2018', 'Drug Manufacturer', '2020-07-04 18:58:50'),
(292, 'HeteroDrugs_03022018_O-5.png', 'Hetero Drugs_03022018_O-A.pdf', 38, '2018-03-02', '2018', 5, 69, '8', 5, '3003510514', 'Hetero Drugs Limited', 'Plot 213, Bonthapally Village\r\n', 'Mandal, Telengana, 502313, India\r\n', 'Mr. J Sambi Reddy, Director Ops\r\n', '02/26/2018 - 03/02/2018', 'Drug Manufacturer', '2020-07-04 18:59:03'),
(293, 'Unichem_07272018_O-1.png', 'Unichem_07272018_O-A.pdf', 39, '2018-07-27', '2018', 5, 29, '52', 1, '3006456888', 'Unichem Laboratories Limited', 'Plot 197 Sec - 1\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Rana Banerjee\r\n', '07/23/2018 - 07/27/2018', 'Drug Manufacturer', '2020-07-01 12:47:22'),
(294, 'Unichem_07272018_O-2.png', 'Unichem_07272018_O-A.pdf', 39, '2018-07-27', '2018', 4, 64, '52', 2, '3006456888', 'Unichem Laboratories Limited', 'Plot 197 Sec - 1\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Rana Banerjee\r\n', '07/23/2018 - 07/27/2018', 'Drug Manufacturer', '2020-07-01 12:51:06'),
(295, 'Unichem_07272018_O-3.png', 'Unichem_07272018_O-A.pdf', 39, '2018-07-27', '2018', 4, 70, '52', 3, '3006456888', 'Unichem Laboratories Limited', 'Plot 197 Sec - 1\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Rana Banerjee\r\n', '07/23/2018 - 07/27/2018', 'Drug Manufacturer', '2020-07-01 12:54:07'),
(296, 'Unichem_07272018_O-4.png', 'Unichem_07272018_O-A.pdf', 39, '2018-07-27', '2018', 1, 52, '52', 4, '3006456888', 'Unichem Laboratories Limited', 'Plot 197 Sec - 1\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Rana Banerjee\r\n', '07/23/2018 - 07/27/2018', 'Drug Manufacturer', '2020-07-01 12:55:55'),
(297, 'Liva Pharma_08282018_O-1.png', 'Liva Pharma_08282018_O-A.pdf', 40, '2018-08-28', '2018', 1, 35, '53', 1, '3013712903', 'Liva Pharmaceuticals Limited', 'Survey - 434 - 6/B, Jarod Waghodiya\r\n', 'Vadodara, Gujarat, 391510, India\r\n', 'Mr. Nitish N. Chakravarty, Chief Manufacturing\r\n', '08/20/2018 - 08/28/2018', 'Drug Manufacturer', '2020-07-01 13:02:20'),
(298, 'Liva Pharma_08282018_O-2.png', 'Liva Pharma_08282018_O-A.pdf', 40, '2018-08-28', '2018', 5, 30, '53', 2, '3013712903', 'Liva Pharmaceuticals Limited', 'Survey - 434 - 6/B, Jarod Waghodiya\r\n', 'Vadodara, Gujarat, 391510, India\r\n', 'Mr. Nitish N. Chakravarty, Chief Manufacturing\r\n', '08/20/2018 - 08/28/2018', 'Drug Manufacturer', '2020-07-01 13:04:21'),
(299, 'Liva Pharma_08282018_O-3.png', 'Liva Pharma_08282018_O-A.pdf', 40, '2018-08-28', '2018', 1, 43, '53', 3, '3013712903', 'Liva Pharmaceuticals Limited', 'Survey - 434 - 6/B, Jarod Waghodiya\r\n', 'Vadodara, Gujarat, 391510, India\r\n', 'Mr. Nitish N. Chakravarty, Chief Manufacturing\r\n', '08/20/2018 - 08/28/2018', 'Drug Manufacturer', '2020-07-01 13:05:51'),
(300, 'Liva Pharma_08282018_O-4.png', 'Liva Pharma_08282018_O-A.pdf', 40, '2018-08-28', '2018', 1, 34, '53', 4, '3013712903', 'Liva Pharmaceuticals Limited', 'Survey - 434 - 6/B, Jarod Waghodiya\r\n', 'Vadodara, Gujarat, 391510, India\r\n', 'Mr. Nitish N. Chakravarty, Chief Manufacturing\r\n', '08/20/2018 - 08/28/2018', 'Drug Manufacturer', '2020-07-01 13:09:30'),
(301, 'Liva Pharma_08282018_O-5.png', 'Liva Pharma_08282018_O-A.pdf', 40, '2018-08-28', '2018', 5, 64, '53', 5, '3013712903', 'Liva Pharmaceuticals Limited', 'Survey - 434 - 6/B, Jarod Waghodiya\r\n', 'Vadodara, Gujarat, 391510, India\r\n', 'Mr. Nitish N. Chakravarty, Chief Manufacturing\r\n', '08/20/2018 - 08/28/2018', 'Drug Manufacturer', '2020-07-01 13:10:59'),
(302, 'Sun Pharma_08312018_O-1.png', 'Sun Pharma_08312018_O-A.pdf', 17, '2018-08-31', '2018', 4, 64, '3,54', 1, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '08/27/2018 - 08/31/2018', 'Manufacturer', '2020-07-08 13:09:04'),
(303, 'Sun Pharma_08312018_O-2.png', 'Sun Pharma_08312018_O-A.pdf', 17, '2018-08-31', '2018', 4, 31, '3,54', 2, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '08/27/2018 - 08/31/2018', 'Manufacturer', '2020-07-08 13:09:07'),
(304, 'Sun Pharma_08312018_O-3.png', 'Sun Pharma_08312018_O-A.pdf', 17, '2018-08-31', '2018', 4, 51, '3,54', 3, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '08/27/2018 - 08/31/2018', 'Manufacturer', '2020-07-08 13:09:11'),
(305, 'Sun Pharma_08312018_O-4.png', 'Sun Pharma_08312018_O-A.pdf', 17, '2018-08-31', '2018', 3, 71, '3,54', 4, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '08/27/2018 - 08/31/2018', 'Manufacturer', '2020-07-08 13:09:14'),
(306, 'Sun Pharma_08312018_O-5.png', 'Sun Pharma_08312018_O-A.pdf', 17, '2018-08-31', '2018', 1, 72, '3,54', 5, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '08/27/2018 - 08/31/2018', 'Manufacturer', '2020-07-08 13:09:23'),
(307, 'Sun Pharma_08312018_O-6.png', 'Sun Pharma_08312018_O-A.pdf', 17, '2018-08-31', '2018', 1, 34, '3,54', 6, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '08/27/2018 - 08/31/2018', 'Manufacturer', '2020-07-08 13:09:28'),
(308, 'Cipla-Salcette_09282018-2019_All-All_O-1.png', 'Cipla-Salcette_09282018-2019_All-All_O-A.pdf', 20, '2018-09-28', '2018', 1, 34, '55,56,57', 1, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/24/2018 - 09/28/2018', 'Pharmaceutical Manufacturer', '2020-07-08 13:09:41'),
(309, 'Cipla-Salcette_09282018-2019_All-All_O-2.png', 'Cipla-Salcette_09282018-2019_All-All_O-A.pdf', 20, '2018-09-28', '2018', 1, 38, '55,56,57', 2, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Site Head\r\n', '09/24/2018 - 09/28/2018', 'Pharmaceutical Manufacturer', '2020-07-08 13:09:56'),
(310, 'Lupin_10182018_O-1.png', 'Lupin_10182018_O-A.pdf', 3, '2018-10-18', '2018', 1, 52, '47', 1, '3009107538', 'Lupin Limited', 'Unit 3, Plot - M 1, Apperal Park\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Amit Sareen, VP & Site Head, Manufacturing\r\n', '10/08/2018 - 10/18/2018', 'Drug Manufacturer', '2020-07-02 05:47:05'),
(311, 'Lupin_10182018_O-2.png', 'Lupin_10182018_O-A.pdf', 3, '2018-10-18', '2018', 5, 29, '47', 2, '3009107538', 'Lupin Limited', 'Unit 3, Plot - M 1, Apperal Park\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Amit Sareen, VP & Site Head, Manufacturing\r\n', '10/08/2018 - 10/18/2018', 'Drug Manufacturer', '2020-07-02 05:48:39'),
(312, 'Lupin_10182018_O-3.png', 'Lupin_10182018_O-A.pdf', 3, '2018-10-18', '2018', 4, 44, '47', 3, '3009107538', 'Lupin Limited', 'Unit 3, Plot - M 1, Apperal Park\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Amit Sareen, VP & Site Head, Manufacturing\r\n', '10/08/2018 - 10/18/2018', 'Drug Manufacturer', '2020-07-02 05:50:25'),
(313, 'Lupin_10182018_O-4.png', 'Lupin_10182018_O-A.pdf', 3, '2018-10-18', '2018', 1, 34, '47', 4, '3009107538', 'Lupin Limited', 'Unit 3, Plot - M 1, Apperal Park\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Amit Sareen, VP & Site Head, Manufacturing\r\n', '10/08/2018 - 10/18/2018', 'Drug Manufacturer', '2020-07-02 05:52:22'),
(314, 'Lupin_10182018_O-5.png', 'Lupin_10182018_O-A.pdf', 3, '2018-10-18', '2018', 4, 51, '47', 5, '3009107538', 'Lupin Limited', 'Unit 3, Plot - M 1, Apperal Park\r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Amit Sareen, VP & Site Head, Manufacturing\r\n', '10/08/2018 - 10/18/2018', 'Drug Manufacturer', '2020-07-02 05:53:58'),
(315, 'Dishman_10262018_O-1.png', 'Dishman_10262018_O-A.pdf', 41, '2018-10-26', '2018', 4, 64, '58', 1, '3004161218', 'Dishman Carbogen Amcis Ltd.', 'Survey - 47, Sanand - Bavla\r\n', 'Ahmedabad, Gujarat, 382220, India\r\n', 'Mr. Janmejay R. Vyas, Chairman\r\n', '10/22/2018 - 10/26/2018', 'Drug Manufacturer', '2020-07-02 05:58:51'),
(316, 'Dishman_10262018_O-2.png', 'Dishman_10262018_O-A.pdf', 41, '2018-10-26', '2018', 4, 64, '58', 2, '3004161218', 'Dishman Carbogen Amcis Ltd.', 'Survey - 47, Sanand - Bavla\r\n', 'Ahmedabad, Gujarat, 382220, India\r\n', 'Mr. Janmejay R. Vyas, Chairman\r\n', '10/22/2018 - 10/26/2018', 'Drug Manufacturer', '2020-07-02 06:00:38'),
(317, 'Dr. Reddy_10302018_O-1.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 3, 57, '21,59', 1, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:26'),
(318, 'Dr. Reddy_10302018_O-2.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 4, 64, '21,59', 2, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:30'),
(319, 'Dr. Reddy_10302018_O-3.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 1, 34, '21,59', 3, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:33'),
(320, 'Dr. Reddy_10302018_O-4.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 5, 39, '21,59', 4, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:37'),
(321, 'Dr. Reddy_10302018_O-5.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 1, 38, '21, 59', 5, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-02 06:13:18'),
(322, 'Dr. Reddy_10302018_O-6.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 1, 43, '21,59', 6, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:42'),
(323, 'Dr. Reddy_10302018_O-7.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 1, 52, '21,59', 7, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:45'),
(324, 'Dr. Reddy_10302018_O-8.png', 'Dr. Reddy_10302018_O-A.pdf', 24, '2018-10-30', '2018', 1, 73, '21,59', 8, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Vikram Shukla, VP - Injectable\r\n', '10/22/2018 - 10/30/2018', 'Drug Manufacturer', '2020-07-08 13:10:48');
INSERT INTO `form483` (`id`, `file_name`, `pdf_name`, `company_name`, `date`, `year`, `category`, `category_sub`, `inspector`, `observation`, `fei`, `firm_name`, `address`, `location`, `name_title`, `date_of_inspection`, `type_of_es`, `createdate`) VALUES
(325, 'Aurobindo-MedakHyderabad_12142018-2019_All-All_O-1.png', 'Aurobindo-MedakHyderabad_12142018-2019_All-All_O-A.pdf', 32, '2018-12-14', '2018', 5, 39, '11', 1, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, VP - Quality\r\n', '12/03/2018 - 12/14/2018', 'Drug Manufacturer', '2020-07-02 06:23:53'),
(326, 'Aurobindo-MedakHyderabad_12142018-2019_All-All_O-2.png', 'Aurobindo-MedakHyderabad_12142018-2019_All-All_O-A.pdf', 32, '2018-12-14', '2018', 5, 74, '11', 2, '3008461619', 'Aurobindo Prarma - Unit IV', 'Plot 4, 34-48 EPIP, IDA Pashamylaram, Pantancheru Mandal\r\n', 'Medak, Hyderabad, Telengana, 502307, India\r\n', 'Mr. Rajesh S. Kulkarni, VP - Quality\r\n', '12/03/2018 - 12/14/2018', 'Drug Manufacturer', '2020-07-02 06:27:09'),
(388, 'DrReddy-BollaramAP_07122019-2019_All-All_O-1.png', 'DrReddy-BollaramAP_07122019-2019_All-All_O-A.pdf', 6, '2019-07-12', '2019', 1, 38, '9,10', 1, '3005448030', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'Plot 1, 75A/B, 105, 110 & 111-112, Sri Venkateswara Co-op Ind.\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Mr. R V Sai Prasad, Site Head\r\n', '07/08/2019 - 07/12/2019', 'API Manufacturer', '2020-07-08 13:10:58'),
(389, 'DrReddy-BollaramAP_07122019-2019_All-All_O-2.png', 'DrReddy-BollaramAP_07122019-2019_All-All_O-A.pdf', 6, '2019-07-12', '2019', 11, 75, '9,10', 2, '3005448030', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'Plot 1, 75A/B, 105, 110 & 111-112, Sri Venkateswara Co-op Ind.\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Mr. R V Sai Prasad, Site Head\r\n', '07/08/2019 - 07/12/2019', 'API Manufacturer', '2020-07-08 13:11:02'),
(390, 'DrReddy-BollaramAP_07122019-2019_All-All_O-3.png', 'DrReddy-BollaramAP_07122019-2019_All-All_O-A.pdf', 6, '2019-07-12', '2019', 11, 76, '9,10', 3, '3005448030', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'Plot 1, 75A/B, 105, 110 & 111-112, Sri Venkateswara Co-op Ind.\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Mr. R V Sai Prasad, Site Head\r\n', '07/08/2019 - 07/12/2019', 'API Manufacturer', '2020-07-08 13:11:06'),
(391, 'DrReddy-BollaramAP_07122019-2019_All-All_O-4.png', 'DrReddy-BollaramAP_07122019-2019_All-All_O-A.pdf', 6, '2019-07-12', '2019', 5, 36, '9,10', 4, '3005448030', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'Plot 1, 75A/B, 105, 110 & 111-112, Sri Venkateswara Co-op Ind.\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Mr. R V Sai Prasad, Site Head\r\n', '07/08/2019 - 07/12/2019', 'API Manufacturer', '2020-07-08 13:11:09'),
(392, 'DrReddy-BollaramAP_07122019-2019_All-All_O-5.png', 'DrReddy-BollaramAP_07122019-2019_All-All_O-A.pdf', 6, '2019-07-12', '2019', 1, 52, '9,10', 5, '3005448030', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'Plot 1, 75A/B, 105, 110 & 111-112, Sri Venkateswara Co-op Ind.\r\n', 'Bollaram, Medak Dist., AP, 502325, India\r\n', 'Mr. R V Sai Prasad, Site Head\r\n', '07/08/2019 - 07/12/2019', 'API Manufacturer', '2020-07-08 13:11:12'),
(393, 'Cipla-Bangalore_07192019-2019_All-All_O-1.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 1, 38, '9,10', 1, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:17'),
(394, 'Cipla-Bangalore_07192019-2019_All-All_O-2.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 5, 18, '9,10', 2, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:20'),
(395, 'Cipla-Bangalore_07192019-2019_All-All_O-3.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 11, 75, '9,10', 3, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:24'),
(396, 'Cipla-Bangalore_07192019-2019_All-All_O-4.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 1, 42, '9,10', 4, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:28'),
(397, 'Cipla-Bangalore_07192019-2019_All-All_O-5.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 4, 49, '9,10', 5, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:31'),
(398, 'Cipla-Bangalore_07192019-2019_All-All_O-6.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 1, 34, '9,10', 6, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:37'),
(399, 'Cipla-Bangalore_07192019-2019_All-All_O-7.png', 'Cipla-Bangalore_07192019-2019_All-All_O-A.pdf', 7, '2019-07-19', '2019', 1, 52, '9,10', 7, '3002806691', 'Cipla Limited, Virgonagar Site', 'Old Madras Road, Virgonagar\r\n', 'Bangalore, Karnataka, 560049, India\r\n', 'Mr. Daniel Boppuri, Senior Director & Site Head\r\n', '07/15/2019 - 07/19/2019', 'API Manufacturer', '2020-07-08 13:11:52'),
(400, 'Indoco-Goa_04062019-2019_All-All_O-1.png', 'Indoco-Goa_04062019-2019_All-All_O-A.pdf', 4, '2019-06-04', '2019', 4, 49, '11', 1, '3005124189', 'Indoco Remedies Limited', 'L 32 33 & 34 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajesh R Desai, Associate VP - Production\r\n', '05/27/2019 - 06/04/2019', 'Drug Manufacturer', '2020-07-02 16:54:51'),
(401, 'Indoco-Goa_04062019-2019_All-All_O-2.png', 'Indoco-Goa_04062019-2019_All-All_O-A.pdf', 4, '2019-06-04', '2019', 1, 38, '11', 2, '3005124189', 'Indoco Remedies Limited', 'L 32 33 & 34 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajesh R Desai, Associate VP - Production\r\n', '05/27/2019 - 06/04/2019', 'Drug Manufacturer', '2020-07-02 16:56:40'),
(402, 'Indoco-Goa_04062019-2019_All-All_O-3.png', 'Indoco-Goa_04062019-2019_All-All_O-A.pdf', 4, '2019-06-04', '2019', 4, 49, '11', 3, '3005124189', 'Indoco Remedies Limited', 'L 32 33 & 34 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajesh R Desai, Associate VP - Production\r\n', '05/27/2019 - 06/04/2019', 'Drug Manufacturer', '2020-07-02 16:58:15'),
(403, 'Indoco-Goa_04062019-2019_All-All_O-4.png', 'Indoco-Goa_04062019-2019_All-All_O-A.pdf', 4, '2019-06-04', '2019', 1, 35, '11', 4, '3005124189', 'Indoco Remedies Limited', 'L 32 33 & 34 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr. Rajesh R Desai, Associate VP - Production\r\n', '05/27/2019 - 06/04/2019', 'Drug Manufacturer', '2020-07-02 17:00:35'),
(404, 'DrReddy-Visakhapatnam_06212019-2019_All-All_O-1.png', 'DrReddy-Visakhapatnam_06212019-2019_All-All_O-A.pdf', 8, '2019-06-21', '2019', 1, 35, '12,13', 1, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Shailesh N Patel, VP\r\n', '06/13/2019 - 06/19/2019', 'Drug Manufacturer', '2020-07-08 13:12:01'),
(405, 'DrReddy-Visakhapatnam_06212019-2019_All-All_O-2.png', 'DrReddy-Visakhapatnam_06212019-2019_All-All_O-A.pdf', 8, '2019-06-21', '2019', 5, 18, '12,13', 2, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Shailesh N Patel, VP\r\n', '06/13/2019 - 06/19/2019', 'Drug Manufacturer', '2020-07-08 13:12:06'),
(406, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-1.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 1, 35, '14', 1, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-02 17:18:20'),
(407, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-2.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 1, 52, '14', 2, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-02 17:23:43'),
(408, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-3.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 5, 29, '14', 3, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-02 17:25:54'),
(409, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-4.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 1, 38, '14', 4, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-02 17:27:53'),
(410, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-5.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 1, 77, '14', 5, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-02 17:31:27'),
(411, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-6.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 1, 45, '14', 6, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-03 05:31:28'),
(412, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-7.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 5, 18, '14', 7, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-03 05:32:59'),
(413, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-8.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 1, 52, '14', 8, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-03 05:35:43'),
(414, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-9.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 5, 36, '14', 9, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-03 05:37:14'),
(415, 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-10.png', 'Aurobindo-MedchalTelangana_05242019-2019_All-All_O-A.pdf', 9, '2019-05-24', '2019', 5, 46, '14', 10, '3004021229', 'Aurobindo Pharma Limited', 'Unit - 3, Survey 313 & 314, Bachupally, Medchal - Malkajgiri Dist.\r\n', 'Medchal, Telangana, 500090, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '05/13/2019 - 05/24/2019', 'Finished Dosage Manufacturer', '2020-07-03 05:39:13'),
(416, 'Lupin-Aurangabad_05152019-2019_All-All_O-1.png', 'Lupin-Aurangabad_05152019-2019_All-All_O-A.pdf', 10, '2019-05-15', '2019', 1, 38, '15', 1, '3004995645', 'Lupin Limited', '28 - 1, MIDC Industrial Area, Chikalthana\r\n', 'Aurangabad, Maharastra, 431210, India\r\n', 'Mr. Rajendra Chunodkar, President - MO\r\n', '05/06/2019 - 05/15/2019', 'Finished Drugs Manufacturer', '2020-07-07 12:12:49'),
(417, 'Lupin-Aurangabad_05152019-2019_All-All_O-2.png', 'Lupin-Aurangabad_05152019-2019_All-All_O-A.pdf', 10, '2019-05-15', '2019', 4, 70, '15', 2, '3004995645', 'Lupin Limited', '28 - 1, MIDC Industrial Area, Chikalthana\r\n', 'Aurangabad, Maharastra, 431210, India\r\n', 'Mr. Rajendra Chunodkar, President - MO\r\n', '05/06/2019 - 05/15/2019', 'Finished Drugs Manufacturer', '2020-07-07 12:12:53'),
(418, 'Lupin-Aurangabad_05152019-2019_All-All_O-3.png', 'Lupin-Aurangabad_05152019-2019_All-All_O-A.pdf', 10, '2019-05-15', '2019', 5, 30, '56', 3, '3004995645', 'Lupin Limited', '28 - 1, MIDC Industrial Area, Chikalthana\r\n', 'Aurangabad, Maharastra, 431210, India\r\n', 'Mr. Rajendra Chunodkar, President - MO\r\n', '05/06/2019 - 05/15/2019', 'Finished Drugs Manufacturer', '2020-07-07 12:13:47'),
(419, 'Cadila-Ahmedabad_05032019-2019_All-All_O-1.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 29, '16,17,18', 1, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:12:27'),
(420, 'Cadila-Ahmedabad_05032019-2019_All-All_O-2.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 39, '16,17,18', 2, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:12:38'),
(421, 'Cadila-Ahmedabad_05032019-2019_All-All_O-3.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 3, 50, '16,17,18', 3, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:12:52'),
(422, 'Cadila-Ahmedabad_05032019-2019_All-All_O-4.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 78, '16,17,18', 4, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:12:55'),
(423, 'Cadila-Ahmedabad_05032019-2019_All-All_O-5.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 30, '16,17,18', 5, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:12:58'),
(424, 'Cadila-Ahmedabad_05032019-2019_All-All_O-6.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 18, '16,17,18', 6, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:15'),
(425, 'Cadila-Ahmedabad_05032019-2019_All-All_O-7.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 66, '16,17,18', 7, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:19'),
(426, 'Cadila-Ahmedabad_05032019-2019_All-All_O-8.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 1, 38, '16,17,18', 8, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:22'),
(427, 'Cadila-Ahmedabad_05032019-2019_All-All_O-9.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 1, 34, '16,17,18', 9, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:25'),
(428, 'Cadila-Ahmedabad_05032019-2019_All-All_O-10.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 46, '16,17,18', 10, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:30'),
(429, 'Cadila-Ahmedabad_05032019-2019_All-All_O-11.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 4, 51, '16,17,18', 11, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:34'),
(430, 'Cadila-Ahmedabad_05032019-2019_All-All_O-12.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 1, 38, '16,17,18', 12, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:38'),
(431, 'Cadila-Ahmedabad_05032019-2019_All-All_O-13.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 5, 18, '16,17,18', 13, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-08 13:13:41'),
(432, 'Cadila-Ahmedabad_05032019-2019_All-All_O-14.png', 'Cadila-Ahmedabad_05032019-2019_All-All_O-A.pdf', 11, '2019-05-03', '2019', 1, 34, '16, 17, 18', 14, '3002984011', 'Cadila Healthcare Limited', '419 & 420 8a Village- Moraiya\r\n', 'Ahmedabad, Gujarat, 382210, India\r\n', 'Mr. Umesh Kumar Gupta, Campus Head\r\n', '04/22/2019 - 05/03/2019', 'Drug Manufacturer', '2020-07-03 06:25:47'),
(433, 'Torrent-Indrad_04162019-2019_All-All_O-1.png', 'Torrent-Indrad_04162019-2019_All-All_O-A.pdf', 12, '2019-04-16', '2019', 4, 64, '2,5,19', 1, '3005029956', 'Torrent Pharmaceuticals Limited', 'Ahmedabad Mehsana Highway, Taluka - Kadi\r\n', 'Indrad, Gujarat, 382721, India\r\n', 'Mr. Ashish Hajarnis, VP - Work', '04/08/2019 - 04/16/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:13:58'),
(434, 'Torrent-Indrad_04162019-2019_All-All_O-2.png', 'Torrent-Indrad_04162019-2019_All-All_O-A.pdf', 12, '2019-04-16', '2019', 1, 42, '2,5,19', 2, '3005029956', 'Torrent Pharmaceuticals Limited', 'Ahmedabad Mehsana Highway, Taluka - Kadi\r\n', 'Indrad, Gujarat, 382721, India\r\n', 'Mr. Ashish Hajarnis, VP - Work\r\n', '04/08/2019 - 04/16/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:14:02'),
(435, 'Torrent-Indrad_04162019-2019_All-All_O-3.png', 'Torrent-Indrad_04162019-2019_All-All_O-A.pdf', 12, '2019-04-16', '2019', 5, 61, '2,5,19', 3, '3005029956', 'Torrent Pharmaceuticals Limited', 'Ahmedabad Mehsana Highway, Taluka - Kadi\r\n', 'Indrad, Gujarat, 382721, India\r\n', 'Mr. Ashish Hajarnis, VP - Work\r\n', '04/08/2019 - 04/16/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:14:05'),
(436, 'Torrent-Indrad_04162019-2019_All-All_O-4.png', 'Torrent-Indrad_04162019-2019_All-All_O-A.pdf', 12, '2019-04-16', '2019', 1, 38, '2,5,19', 4, '3005029956', 'Torrent Pharmaceuticals Limited', 'Ahmedabad Mehsana Highway, Taluka - Kadi\r\n', 'Indrad, Gujarat, 382721, India\r\n', 'Mr. Ashish Hajarnis, VP - Work\r\n', '04/08/2019 - 04/16/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:14:10'),
(437, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-1.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 35, '20,21,22', 1, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:19'),
(438, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-2.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 45, '20,21,22', 2, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:03:51'),
(439, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-3.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 38, '20,21,22', 3, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:31'),
(440, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-4.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 43, '20,21,22', 4, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:34'),
(441, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-5.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 5, 39, '20,21,22', 5, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:37'),
(442, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-6.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 3, 50, '20,21,22', 6, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:42'),
(443, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-7.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 4, 40, '20,21,22', 7, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:44'),
(444, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-8.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 63, '20,21,22', 8, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:14:59'),
(445, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-9.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 79, '20,21,22', 9, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:15:03'),
(446, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-10.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 1, 52, '20,21,22', 10, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:15:06'),
(447, 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-11.png', 'Aurobindo-Mahabubnagar_03012019-2019_All-All_O-A.pdf', 13, '2019-03-01', '2019', 4, 40, '20,21,22', 11, '3011905047', 'Aurobindo Pharma Limited', 'Unit - XVI, SEZ, Plot No. S-5/A, S-6 & S-7, Polepally, Jadcherla Mandal\r\n', 'Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '02/22/2019 - 03/01/2019', 'Manufacturer of sterile Drug Products', '2020-07-08 13:15:18'),
(448, 'Sunpharma-Halol_05022019-2019_All-All_O-1.png', 'Sunpharma-Halol_05022019-2019_All-All_O-A.pdf', 14, '2019-02-05', '2019', 4, 64, '34', 1, '3002957541', 'Sun Pharmaceutical Medicare Limited', 'Survey No. 22 & 24, Ujeti, Baska, Panchamahal\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pankaj Shitole, SGM - Operation\r\n', '01/28/2019 - 02/05/2019', 'Pharmaceutical Manufacturer', '2020-07-07 12:12:03'),
(449, 'Biocon-Bangalore_02152019-2019_All-All_O-1.png', 'Biocon-Bangalore_02152019-2019_All-All_O-A.pdf', 15, '2019-02-15', '2019', 3, 80, '24,25', 1, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Srinivasan Raman, SVP & GH - Drug Prod. Ops\r\n', '02/07/2019 - 02/15/2019', 'Drug Manufacturer', '2020-07-08 13:15:42'),
(450, 'Biocon-Bangalore_02152019-2019_All-All_O-2.png', 'Biocon-Bangalore_02152019-2019_All-All_O-A.pdf', 15, '2019-02-15', '2019', 5, 30, '24,25', 2, '3003981475', 'Biocon Limited', 'Plot No 2 to 5, Bommasandre Jigani Link Road\r\n', 'Bangalore, Karnataka, 560099, India\r\n', 'Mr. Srinivasan Raman, SVP & GH - Drug Prod. Ops\r\n', '02/07/2019 - 02/15/2019', 'Drug Manufacturer', '2020-07-08 13:15:48'),
(451, 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-1.png', 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-A.pdf', 16, '2019-01-15', '2019', 4, 64, '16,15', 1, '3009193040', 'Dr. Reddy''s Laboratories Limited', 'FTO - SEZ, Unit 1, Serv. 59-60, 62 & 72, Sec - 9-14, 17-20, Devunipalavalasa\r\n', 'Ranasthalam Mandal, Shrikakulam, AP, 532409, India\r\n', 'Mr. Ganadhish Kamat, EVP & GH - Quality\r\n', '01/07/2019 - 01/15/2019', 'Drug Manufacturer', '2020-07-08 13:15:55'),
(452, 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-2.png', 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-A.pdf', 16, '2019-01-15', '2019', 1, 63, '16,15', 2, '3009193040', 'Dr. Reddy''s Laboratories Limited', 'FTO - SEZ, Unit 1, Serv. 59-60, 62 & 72, Sec - 9-14, 17-20, Devunipalavalasa\r\n', 'Ranasthalam Mandal, Shrikakulam, AP, 532409, India\r\n', 'Mr. Ganadhish Kamat, EVP & GH - Quality\r\n', '01/07/2019 - 01/15/2019', 'Drug Manufacturer', '2020-07-08 13:15:58'),
(453, 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-3.png', 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-A.pdf', 16, '2019-01-15', '2019', 4, 51, '16,15', 3, '3009193040', 'Dr. Reddy''s Laboratories Limited', 'FTO - SEZ, Unit 1, Serv. 59-60, 62 & 72, Sec - 9-14, 17-20, Devunipalavalasa\r\n', 'Ranasthalam Mandal, Shrikakulam, AP, 532409, India\r\n', 'Mr. Ganadhish Kamat, EVP & GH - Quality\r\n', '01/07/2019 - 01/15/2019', 'Drug Manufacturer', '2020-07-08 13:16:04'),
(454, 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-4.png', 'DrReddy-RanasthalamAP_01152019-2019_All-All_O-A.pdf', 16, '2019-01-15', '2019', 1, 34, '15,16', 4, '3009193040', 'Dr. Reddy''s Laboratories Limited', 'FTO - SEZ, Unit 1, Serv. 59-60, 62 & 72, Sec - 9-14, 17-20, Devunipalavalasa\r\n', 'Ranasthalam Mandal, Shrikakulam, AP, 532409, India\r\n`', 'Mr. Ganadhish Kamat, EVP & GH - Quality\r\n', '01/07/2019 - 01/15/2019', 'Drug Manufacturer', '2020-07-08 13:16:07'),
(455, 'Sunpharma-Halol_12132019-2019_All-All_O-1.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 4, 64, '21,26,27', 1, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:16:20'),
(456, 'Sunpharma-Halol_12132019-2019_All-All_O-2.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 1, 52, '21,26,27', 2, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:16:26'),
(457, 'Sunpharma-Halol_12132019-2019_All-All_O-3.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 4, 51, '21,26,27', 3, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:16:31'),
(458, 'Sunpharma-Halol_12132019-2019_All-All_O-4.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 1, 54, '21,26,27', 4, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol - Baroda Highway\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:17:12'),
(459, 'Sunpharma-Halol_12132019-2019_All-All_O-5.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 5, 39, '21,26,27', 5, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:17:18'),
(460, 'Sunpharma-Halol_12132019-2019_All-All_O-6.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 1, 81, '21,26,27', 6, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:17:22'),
(461, 'Sunpharma-Halol_12132019-2019_All-All_O-7.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 1, 81, '21,26,27', 7, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:17:25'),
(462, 'Sunpharma-Halol_12132019-2019_All-All_O-8.png', 'Sunpharma-Halol_12132019-2019_All-All_O-A.pdf', 17, '2019-12-13', '2019', 1, 77, '21,26,27', 8, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '12/03/2019 - 12/13/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-08 13:17:27'),
(464, 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-2.png', 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-A.pdf', 18, '2019-10-25', '2019', 1, 38, '28,29', 2, '3004086884', 'Aurobindo Pharma Limited Unit VIII', 'Survey No. JO & 13, Gaddapotharam Village IDA Kazipally\r\n', 'Jinnaram Manda!, Sangareddy District, Telangana, 502319 lndia\r\n', 'Mr. Mallikarjuna Reddy Kurre, GM - Operations\r\n', '10/21/2019 - 10/25/2019', 'APl Manufacturer', '2020-07-08 13:17:32'),
(465, 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-1.png', 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-A.pdf', 18, '2019-10-25', '2019', 5, 29, '28,29', 1, '3004086884', 'Aurobindo Pharma Limited Unit VIII', 'Survey No. JO & 13, Gaddapotharam Village IDA Kazipally\r\n', 'Jinnaram Manda!, Sangareddy District, Telangana, 502319 lndia\r\n', 'Mr. Mallikarjuna Reddy Kurre, GM - Operations\r\n', '10/21/2019 - 10/25/2019', 'APl Manufacturer', '2020-07-08 13:17:39'),
(466, 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-3.png', 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-A.pdf', 18, '2019-10-25', '2019', 1, 82, '28,29', 3, '3004086884', 'Aurobindo Pharma Limited Unit VIII', 'Survey No. JO & 13, Gaddapotharam Village IDA Kazipally\r\n', 'Jinnaram Manda!, Sangareddy District, Telangana, 502319 lndia\r\n', 'Mr. Mallikarjuna Reddy Kurre, GM - Operations\r\n', '10/21/2019 - 10/25/2019', 'APl Manufacturer', '2020-07-08 13:17:43'),
(467, 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-4.png', 'Aurobindo-JinnaramTelangana_10252019-2019_All-All_O-A.pdf', 18, '2019-10-25', '2019', 1, 52, '28,29', 4, '3004086884', 'Aurobindo Pharma Limited Unit VIII', 'Survey No. JO & 13, Gaddapotharam Village IDA Kazipally\r\n', 'Jinnaram Manda!, Sangareddy District, Telangana, 502319 lndia\r\n', 'Mr. Mallikarjuna Reddy Kurre, GM - Operations\r\n', '10/21/2019 - 10/25/2019', 'APl Manufacturer', '2020-07-08 13:17:47'),
(468, 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-1.png', 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-A.pdf', 19, '2019-10-28', '2019', 4, 64, '30', 1, '3004051616', 'Aurobindo Pharma Limited Unit V', 'Plot 68-70,73-91 ,95,96,260 & 261 , IDA Chemical Zone\r\n', 'Pashamylaram,Patancheru,Sanga Reddy,Telangana, 502307, India\r\n', 'Mr. Bhagwat Patil, SGM - Operations\r\n', '10/21/2019 - 10/28/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-03 10:10:12'),
(469, 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-2.png', 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-A.pdf', 19, '2019-10-28', '2019', 5, 39, '30', 2, '3004051616', 'Aurobindo Pharma Limited Unit V', 'Plot 68-70,73-91 ,95,96,260 & 261 , IDA Chemical Zone\r\n', 'Pashamylaram,Patancheru,Sanga Reddy,Telangana, 502307, India\r\n', 'Mr. Bhagwat Patil, SGM - Operations\r\n', '10/21/2019 - 10/28/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-03 10:11:40'),
(470, 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-3.png', 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-A.pdf', 19, '2019-10-28', '2019', 5, 46, '30', 3, '3004051616', 'Aurobindo Pharma Limited Unit VIII', 'Plot 68-70,73-91 ,95,96,260 & 261 , IDA Chemical Zone\r\n', 'Pashamylaram,Patancheru,Sanga Reddy,Telangana, 502307, India\r\n', 'Mr. Bhagwat Patil, SGM - Operations\r\n', '10/21/2019 - 10/28/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-03 10:13:48'),
(471, 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-4.png', 'Aurobindo-PashamylaramTelangana_10282019-2019_All-All_O-A.pdf', 19, '2019-10-28', '2019', 1, 42, '30', 4, '3004051616', 'Aurobindo Pharma Limited Unit VIII', 'Plot 68-70,73-91 ,95,96,260 & 261 , IDA Chemical Zone\r\n', 'Pashamylaram,Patancheru,Sanga Reddy,Telangana, 502307, India\r\n', 'Mr. Bhagwat Patil, SGM - Operations', '10/21/2019 - 10/28/2019', 'Sterile and Non-Sterile Drug Manufacturer ', '2020-07-03 10:15:12'),
(472, 'Cipla-Goa_09272019-2019_All-All_O-1.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 29, '31,32,33', 1, '3004081307', 'Cipla Limited, Virgonagar Site', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:17:59'),
(473, 'Cipla-Goa_09272019-2019_All-All_O-2.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 18, '31,32,33', 2, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:03'),
(474, 'Cipla-Goa_09272019-2019_All-All_O-3.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 39, '31,32,33', 3, '3004081307', 'Cipla Limited, Virgonagar Site', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:06'),
(475, 'Cipla-Goa_09272019-2019_All-All_O-4.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 18, '31,32,33', 4, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:23'),
(476, 'Cipla-Goa_09272019-2019_All-All_O-5.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 1, 34, '31,32,33', 5, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:29'),
(477, 'Cipla-Goa_09272019-2019_All-All_O-6.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 1, 42, '31,32,33', 6, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:35'),
(478, 'Cipla-Goa_09272019-2019_All-All_O-7.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 29, '31,32,33', 7, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:38'),
(479, 'Cipla-Goa_09272019-2019_All-All_O-8.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 1, 34, '31,32,33', 8, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:44'),
(480, 'Cipla-Goa_09272019-2019_All-All_O-9.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 36, '31,32,33', 9, '3004081307', 'Cipla Limited, Virgonagar Site', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:47'),
(481, 'Cipla-Goa_09272019-2019_All-All_O-10.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 5, 18, '31,32,33', 10, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:50'),
(482, 'Cipla-Goa_09272019-2019_All-All_O-11.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 1, 38, '31,32,33', 11, '3004081307', 'Cipla Limited, Virgonagar Site', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:55'),
(483, 'Cipla-Goa_09272019-2019_All-All_O-12.png', 'Cipla-Goa_09272019-2019_All-All_O-A.pdf', 20, '2019-09-27', '2019', 1, 35, '31,32,33', 12, '3004081307', 'Cipla Limited', '"L129 - 146 S - 1 03 - 1 05 S - 1 07 - 112\r\nL147 - L147 1"\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Mr . Ashwin Upasane, Sit e Head\r\n', '09/16/2019 - 09/27/2019', 'Pharmaceutical Manufacturer', '2020-07-08 13:18:58'),
(484, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-1.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 1, 38, '5,34,35', 1, '3007373532', 'Aurobindo Pharma Limited Unit VIII', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:12'),
(485, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-2.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 1, 52, '5,34,35', 2, '3007373532', 'Aurobindo Pharma Limited', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:15'),
(486, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-3.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 1, 42, '5,34,35', 3, '3007373532', 'Aurobindo Pharma Limited Unit VIII', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:20'),
(487, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-4.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 4, 51, '5,34,35', 4, '3007373532', 'Aurobindo Pharma Limited Unit V', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:34'),
(488, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-5.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 1, 35, '5,34,35', 5, '3007373532', 'Aurobindo Pharma Limited', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:37'),
(489, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-6.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 5, 29, '5,34,35', 6, '3007373532', 'Aurobindo Pharma Limited Unit VIII', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:40'),
(490, 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-7.png', 'Aurobindo-PolepallyTelangana_09272019-2019_All-All_O-A.pdf', 21, '2019-09-27', '2019', 1, 35, '5,34,35', 7, '3007373532', 'Aurobindo Pharma Limited Unit VIII', 'Unit VII, Formula Plant, Green Ind. Park\r\n', 'Polepally, Mahabubnagar, Telangana, 509302, India\r\n', 'Mr. M Madan Mohan Reddy, Director\r\n', '09/19/2019 - 09/27/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:45'),
(491, 'Lupin-Tarapur_09202019-2019_All-All_O-1.png', 'Lupin-Tarapur_09202019-2019_All-All_O-A.pdf', 22, '2019-09-20', '2019', 1, 38, '1', 1, '3002807512', 'Lupin Limited', 'T- 142 , M. I.D. C . Tarapur Via Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr . Vi jay A. Kothiwale , Site Head & SVP - Manufacturing\r\n', '09/16/2019 - 09/20/2019', 'APl Manufacturer', '2020-07-03 11:37:09'),
(492, 'Lupin-Tarapur_09202019-2019_All-All_O-2.png', 'Lupin-Tarapur_09202019-2019_All-All_O-A.pdf', 22, '2019-09-20', '2019', 1, 81, '1', 2, '3002807512', 'Lupin Limited', 'T- 142 , M. I.D. C . Tarapur Via Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr . Vi jay A. Kothiwale , Site Head & SVP - Manufacturing\r\n', '09/16/2019 - 09/20/2019', 'APl Manufacturer', '2020-07-03 11:38:34'),
(493, 'Lupin-Tarapur_09202019-2019_All-All_O-3.png', 'Lupin-Tarapur_09202019-2019_All-All_O-A.pdf', 22, '2019-09-20', '2019', 5, 46, '1', 3, '3002807512', 'Lupin Limited', 'T- 142 , M. I.D. C . Tarapur Via Boisar\r\n', 'Tarapur , Thane, Maharashtra , 401506, India\r\n', 'Mr . Vi jay A. Kothiwale , Site Head & SVP - Manufacturing\r\n', '09/16/2019 - 09/20/2019', 'APl Manufacturer', '2020-07-03 11:40:25'),
(494, 'Ipca-Silvasa_08232019-2019_All-All_O-1.png', 'Ipca-Silvasa_08232019-2019_All-All_O-A.pdf', 23, '2019-08-23', '2019', 1, 35, '14,36', 1, '3005977675', 'Ipca Laboratories Limited', '"Plot No . 65 And 99, Danudyog, Ind .\r\nEstate, Piparia"\r\n', 'Silvasa (D And Nh), 396230 India\r\n', 'Mr . Sujit Kumar Rath, SGM - Operations\r\n', '08/19/2019- 08/23/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:51'),
(495, 'Ipca-Silvasa_08232019-2019_All-All_O-2.png', 'Ipca-Silvasa_08232019-2019_All-All_O-A.pdf', 23, '2019-08-23', '2019', 1, 83, '14,36', 2, '3005977675', 'Ipca Laboratories Limited', '"Plot No . 65 And 99, Danudyog, Ind .\r\nEstate, Piparia"\r\n', 'Silvasa (D And Nh), 396230 India\r\n', 'Mr . Sujit Kumar Rath, SGM - Operations\r\n', '08/19/2019- 08/23/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:54'),
(496, 'Ipca-Silvasa_08232019-2019_All-All_O-3.png', 'Ipca-Silvasa_08232019-2019_All-All_O-A.pdf', 23, '2019-08-23', '2019', 1, 35, '14,36', 3, '3005977675', 'Ipca Laboratories Limited', '"Plot No . 65 And 99, Danudyog, Ind .\r\nEstate, Piparia"\r\n', 'Silvasa (D And Nh), 396230 India\r\n', 'Mr . Sujit Kumar Rath, SGM - Operations\r\n', '08/19/2019- 08/23/2019', 'Finished Drugs Manufacturer', '2020-07-08 13:19:59'),
(497, 'DrReddy-Duvvada_08202019-2019_All-All_O-1.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 5, 39, '17,37', 1, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:20:53'),
(498, 'DrReddy-Duvvada_08202019-2019_All-All_O-2.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 5, 36, '17,37', 2, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:20:57'),
(499, 'DrReddy-Duvvada_08202019-2019_All-All_O-3.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 1, 38, '17,37', 3, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:21:00'),
(500, 'DrReddy-Duvvada_08202019-2019_All-All_O-4.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 5, 30, '17,37', 4, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:21:23'),
(501, 'DrReddy-Duvvada_08202019-2019_All-All_O-5.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 5, 46, '17,37', 5, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:21:39'),
(502, 'DrReddy-Duvvada_08202019-2019_All-All_O-6.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 1, 34, '17,37', 6, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:21:46'),
(503, 'DrReddy-Duvvada_08202019-2019_All-All_O-7.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 1, 82, '17,37', 7, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:21:49');
INSERT INTO `form483` (`id`, `file_name`, `pdf_name`, `company_name`, `date`, `year`, `category`, `category_sub`, `inspector`, `observation`, `fei`, `firm_name`, `address`, `location`, `name_title`, `date_of_inspection`, `type_of_es`, `createdate`) VALUES
(504, 'DrReddy-Duvvada_08202019-2019_All-All_O-8.png', 'DrReddy-Duvvada_08202019-2019_All-All_O-A.pdf', 24, '2019-08-20', '2019', 1, 83, '17,37', 8, '3006549835', 'Dr. Reddy''s Laboratories Limited', 'P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada\r\n', 'Visakhapatnam, AP, 530046, India\r\n', 'Mr. Sanjay Sharma, EVP & GH - Operations\r\n', '08/12/2019 - 08/20/2019', 'Drug Manufacturer', '2020-07-08 13:21:56'),
(505, 'Sunpharma-Halol_06112019-2019_All-All_O-1.png', 'Sunpharma-Halol_06112019-2019_All-All_O-A.pdf', 17, '2019-06-11', '2019', 3, 50, '12,13,39,40', 1, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '06/03/2019 - 06/11/2019', 'Manufacturer', '2020-07-08 13:22:06'),
(506, 'Sunpharma-Halol_06112019-2019_All-All_O-2.png', 'Sunpharma-Halol_06112019-2019_All-All_O-A.pdf', 17, '2019-06-11', '2019', 4, 51, '12,13,39,40', 2, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '06/03/2019 - 06/11/2019', 'Manufacturer', '2020-07-08 13:22:09'),
(507, 'Sunpharma-Halol_06112019-2019_All-All_O-3.png', 'Sunpharma-Halol_06112019-2019_All-All_O-A.pdf', 17, '2019-06-11', '2019', 1, 35, '12,13,39,40', 3, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '06/03/2019 - 06/11/2019', 'Manufacturer', '2020-07-08 13:22:15'),
(508, 'Sunpharma-Halol_06112019-2019_All-All_O-4.png', 'Sunpharma-Halol_06112019-2019_All-All_O-A.pdf', 17, '2019-06-11', '2019', 5, 36, '12,13,39,40', 4, '3002809586', 'Sun Pharmaceutical Industries Limited', 'Halol - Baroda Highway\r\n', 'Halol, Gujarat, 389350, India\r\n', 'Mr. Pradipta Swain, VP - Operations\r\n', '06/03/2019 - 06/11/2019', 'Manufacturer', '2020-07-08 13:22:21'),
(509, 'Lupin-SalcetteGoa_02082019-2019_O-1.png', 'Lupin-SalcetteGoa_02082019-2019_All-All_O-A.pdf', 1, '2019-02-08', '2019', 1, 38, '1,2', 1, '3004819820', 'Lupin Limited', 'B - 15, Phase A1, Verna Industrial Area\r\n', 'Verna, Salcette, Goa - 403722, India\r\n', 'Mr. Shrinivas Rao Kalakuntla - SGM & Site - Mfg\r\n', '01/28/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:25'),
(510, 'Lupin-SalcetteGoa_02082019-2019_O-2.png', 'Lupin-SalcetteGoa_02082019-2019_All-All_O-A.pdf', 1, '2019-02-08', '2019', 1, 34, '1,2', 2, '3004819820', 'Lupin Limited', 'B - 15, Phase A1, Verna Industrial Area\r\n', 'Verna, Salcette, Goa - 403722, India\r\n', 'Mr. Shrinivas Rao Kalakuntla - SGM & Site - Mfg\r\n', '01/28/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:31'),
(511, 'DrReddy-Telangana_02082019-2019_O-1.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 1, 45, '3,4', 1, '3002949099', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:37'),
(512, 'DrReddy-Telangana_02082019-2019_O-2.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 4, 64, '3,4', 2, '3002949099', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:41'),
(513, 'DrReddy-Telangana_02082019-2019_O-3.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 1, 45, '3,4', 3, '3002949099', 'Dr. Reddy''s Laboratories Ltd.', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:44'),
(514, 'DrReddy-Telangana_02082019-2019_O-4.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 4, 51, '3,4', 4, '3002949099', 'Dr. Reddy''s Laboratories Ltd.', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:48'),
(515, 'DrReddy-Telangana_02082019-2019_O-5.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 1, 34, '3,4', 5, '3002949099', 'Dr. Reddy''s Laboratories Ltd.', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:54'),
(516, 'DrReddy-Telangana_02082019-2019_O-6.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 1, 81, '3,4', 6, '3002949099', 'Dr. Reddy''s Laboratories Ltd.', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:22:58'),
(517, 'DrReddy-Telangana_02082019-2019_O-7.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 4, 51, '3,4', 7, '3002949099', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:23:01'),
(518, 'DrReddy-Telangana_02082019-2019_O-8.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 1, 34, '3,4', 8, '3002949099', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:23:08'),
(519, 'DrReddy-Telangana_02082019-2019_O-9.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 5, 30, '3,4', 9, '3002949099', 'Dr. Reddy''s Laboratories Ltd.', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:23:11'),
(520, 'DrReddy-Telangana_02082019-2019_O-10.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 5, 46, '3,4', 10, '3002949099', 'Dr. Reddy''s Laboratories Ltd. (Unit II)', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:23:14'),
(521, 'DrReddy-Telangana_02082019-2019_O-11.png', 'DrReddy-Telangana_02082019-2019_All-All_O-A.pdf', 2, '2019-02-08', '2019', 5, 46, '3,4', 11, '3002949099', 'Dr. Reddy''s Laboratories Ltd.', 'No. 41, Quthbullapur Mandal\r\n', 'Bachupally, Telangana, 500090, India\r\n', 'Mr. Venkata Narayan Venkatanarayan, VP Site Head\r\n', '01/30/2019 - 02/08/2019', 'Drug Manufacturer', '2020-07-08 13:23:17'),
(522, 'Lupin-Pithampur_01252019-2019_O-1.png', 'Lupin-Pithampur_01252019-2019_All-All_O-A.pdf', 3, '2019-01-25', '2019', 1, 38, '5', 1, '3007549629', 'Lupin Limited', 'Unit - 2, Plot No. M-2 & M-2-A, SEZ Phase II, Misc Zone, Apparel Park, Dist - Dhar, \r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Nilesh D. Gupta, MD\r\n', '01/14/2019 - 25/01/2019', 'Drug Manufacturer', '2020-07-04 18:01:30'),
(523, 'Lupin-Pithampur_01252019-2019_O-2.png', 'Lupin-Pithampur_01252019-2019_All-All_O-A.pdf', 3, '2019-01-25', '2019', 1, 45, '5', 2, '3007549629', 'Lupin Limited', 'Unit - 2, Plot No. M-2 & M-2-A, SEZ Phase II, Misc Zone, Apparel Park, Dist - Dhar, \r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Nilesh D. Gupta, MD\r\n', '01/14/2019 - 25/01/2019', 'Drug Manufacturer', '2020-07-04 18:03:57'),
(524, 'Lupin-Pithampur_01252019-2019_O-3.png', 'Lupin-Pithampur_01252019-2019_All-All_O-A.pdf', 3, '2019-01-25', '2019', 1, 43, '5', 3, '3007549629', 'Lupin Limited', 'Unit - 2, Plot No. M-2 & M-2-A, SEZ Phase II, Misc Zone, Apparel Park, Dist - Dhar, \r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Nilesh D. Gupta, MD\r\n', '01/14/2019 - 25/01/2019', 'Drug Manufacturer', '2020-07-04 18:05:25'),
(525, 'Lupin-Pithampur_01252019-2019_O-4.png', 'Lupin-Pithampur_01252019-2019_All-All_O-A.pdf', 3, '2019-01-25', '2019', 1, 63, '5', 4, '3007549629', 'Lupin Limited', 'Unit - 2, Plot No. M-2 & M-2-A, SEZ Phase II, Misc Zone, Apparel Park, Dist - Dhar, \r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Nilesh D. Gupta, MD\r\n', '01/14/2019 - 25/01/2019', 'Drug Manufacturer', '2020-07-04 18:06:55'),
(526, 'Lupin-Pithampur_01252019-2019_O-5.png', 'Lupin-Pithampur_01252019-2019_All-All_O-A.pdf', 3, '2019-01-25', '2019', 5, 18, '5', 5, '3007549629', 'Lupin Limited', 'Unit - 2, Plot No. M-2 & M-2-A, SEZ Phase II, Misc Zone, Apparel Park, Dist - Dhar, \r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Nilesh D. Gupta, MD\r\n', '01/14/2019 - 25/01/2019', 'Drug Manufacturer', '2020-07-04 18:09:11'),
(527, 'Lupin-Pithampur_01252019-2019_O-6.png', 'Lupin-Pithampur_01252019-2019_All-All_O-A.pdf', 3, '2019-01-25', '2019', 1, 34, '5', 6, '3007549629', 'Lupin Limited', 'Unit - 2, Plot No. M-2 & M-2-A, SEZ Phase II, Misc Zone, Apparel Park, Dist - Dhar, \r\n', 'Pithampur, Madhya Pradesh, 454775, India\r\n', 'Mr. Nilesh D. Gupta, MD\r\n', '01/14/2019 - 25/01/2019', 'Drug Manufacturer', '2020-07-04 18:10:45'),
(528, 'IndocoRem-Goa_01252019-2019_O-1.png', 'IndocoRem-Goa_01252019-2019_All-All_O-A.pdf', 4, '2019-01-25', '2019', 1, 81, '16,15', 1, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Aditi Panandikar, MD\r\n', '01/17/2019 - 25/01/2019', 'Tablet Manufacturer', '2020-07-08 13:24:11'),
(529, 'IndocoRem-Goa_01252019-2019_O-2.png', 'IndocoRem-Goa_01252019-2019_All-All_O-A.pdf', 4, '2019-01-25', '2019', 4, 64, '16,15', 2, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Aditi Panandikar, MD\r\n', '01/17/2019 - 25/01/2019', 'Tablet Manufacturer', '2020-07-08 13:24:24'),
(530, 'IndocoRem-Goa_01252019-2019_O-3.png', 'IndocoRem-Goa_01252019-2019_All-All_O-A.pdf', 4, '2019-01-25', '2019', 1, 52, '16,15', 3, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Aditi Panandikar, MD\r\n', '01/17/2019 - 25/01/2019', 'Tablet Manufacturer', '2020-07-08 13:24:45'),
(531, 'IndocoRem-Goa_01252019-2019_O-4.png', 'IndocoRem-Goa_01252019-2019_All-All_O-A.pdf', 4, '2019-01-25', '2019', 1, 84, '16,15', 4, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Aditi Panandikar, MD\r\n', '01/17/2019 - 25/01/2019', 'Tablet Manufacturer', '2020-07-08 13:24:51'),
(532, 'IndocoRem-Goa_01252019-2019_O-5.png', 'IndocoRem-Goa_01252019-2019_All-All_O-A.pdf', 4, '2019-01-25', '2019', 4, 51, '16,15', 5, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Aditi Panandikar, MD\r\n', '01/17/2019 - 25/01/2019', 'Tablet Manufacturer', '2020-07-08 13:24:57'),
(533, 'IndocoRem-Goa_01252019-2019_O-6.png', 'IndocoRem-Goa_01252019-2019_All-All_O-A.pdf', 4, '2019-01-25', '2019', 5, 85, '16,15', 6, '3006644152', 'Indoco Remedies Limited (Plant I)', 'L - 14 IDC Verna Industrial Road\r\n', 'Vasco Da Gama, Goa, 403722, India\r\n', 'Aditi Panandikar, MD\r\n', '01/17/2019 - 25/01/2019', 'Tablet Manufacturer', '2020-07-08 13:25:04'),
(534, 'ShilpaMedi-RaichurKarnatak_07262019-2019_O-1.png', 'ShilpaMedi-RaichurKarnatak_07262019-2019_All-All_O-A.pdf', 5, '2019-07-26', '2019', 1, 38, '8', 1, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. Vishnukant Bhutada, MD\r\n', '07/22/2019 - 07/26/2019 ', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-04 18:42:34'),
(535, 'ShilpaMedi-RaichurKarnatak_07262019-2019_O-2.png', 'ShilpaMedi-RaichurKarnatak_07262019-2019_All-All_O-A.pdf', 5, '2019-07-26', '2019', 1, 86, '8', 2, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. Vishnukant Bhutada, MD\r\n', '07/22/2019 - 07/26/2019 ', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-04 18:44:59'),
(536, 'ShilpaMedi-RaichurKarnatak_07262019-2019_O-3.png', 'ShilpaMedi-RaichurKarnatak_07262019-2019_All-All_O-A.pdf', 5, '2019-07-26', '2019', 5, 61, '8', 3, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. Vishnukant Bhutada, MD\r\n', '07/22/2019 - 07/26/2019 ', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-04 18:47:15'),
(537, 'ShilpaMedi-RaichurKarnatak_07262019-2019_O-4.png', 'ShilpaMedi-RaichurKarnatak_07262019-2019_All-All_O-A.pdf', 5, '2019-07-26', '2019', 5, 66, '8', 4, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. Vishnukant Bhutada, MD\r\n', '07/22/2019 - 07/26/2019 ', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-04 18:49:06'),
(538, 'ShilpaMedi-RaichurKarnatak_07262019-2019_O-5.png', 'ShilpaMedi-RaichurKarnatak_07262019-2019_All-All_O-A.pdf', 5, '2019-07-26', '2019', 5, 87, '8', 5, '3007197995', 'Shilpa Medicare Limited', '33 33A & 40 To 47 Raichur Industrial Growth Centre, Chicksugur\r\n', 'Raichur, Karnataka, 5841734, India\r\n', 'Mr. Vishnukant Bhutada, MD\r\n', '07/22/2019 - 07/26/2019 ', 'Active Pharmaceutical Ingredients Manufacturer', '2020-07-04 18:51:53'),
(540, 'Hospira Healthcare_04032018_O-7.png', 'Hospira Healthcare_04032018_O-A.pdf', 26, '2018-04-03', '2018', 3, 50, '21,43', 7, '3008386908', 'Hospira Healthcare India Private Limited', 'Plot B3 - B6 & Others\r\n', 'Sriperumbudur, Tamil Nadu, 602105, India\r\n', 'Simon W. Beunsch, Site Leader\r\n', '03/27/2018 - 04/03/2018', 'Drug Manufacturer', '2020-07-06 10:17:57');

-- --------------------------------------------------------

--
-- Table structure for table `guest_blog`
--

CREATE TABLE IF NOT EXISTS `guest_blog` (
  `id` int(11) NOT NULL,
  `name` varchar(50) NOT NULL,
  `email` varchar(50) NOT NULL,
  `phone` varchar(50) NOT NULL,
  `website` varchar(50) NOT NULL,
  `blog_title` varchar(255) NOT NULL,
  `image` varchar(100) NOT NULL,
  `description` varchar(1000) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `guest_blog`
--

INSERT INTO `guest_blog` (`id`, `name`, `email`, `phone`, `website`, `blog_title`, `image`, `description`, `createdate`) VALUES
(1, 'Binjal', 'binjal308@gmail.com', '2020-02-12', 'www.xyz.com', 'Test Title', 'promobg2.jpg', 'This is test.\r\nThis is test.\r\nThis is test.\r\nThis is test.\r\nThis is test.\r\nThis is test.This is test.\r\nThis is test.', '2020-02-11 11:44:16'),
(2, 'Palak', 'pdd@gmail.com', '2020-02-07', '', 'Test Blog', 'slide3.jpg', 'This is test Blog...', '2020-02-11 11:46:04');

-- --------------------------------------------------------

--
-- Table structure for table `inspector`
--

CREATE TABLE IF NOT EXISTS `inspector` (
  `id` int(11) NOT NULL,
  `name` varchar(500) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=60 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `inspector`
--

INSERT INTO `inspector` (`id`, `name`, `createdate`) VALUES
(1, 'Unnee Ranjan', '2020-02-07 06:24:51'),
(2, 'Lata C. Mathew', '2020-02-07 06:24:51'),
(3, 'Angela E. Glenn', '2020-02-07 06:25:14'),
(4, 'Cheryl A. Clausen', '2020-02-07 06:25:14'),
(5, 'Jogy George', '2020-02-07 06:25:38'),
(8, 'Yvins Dezan', '2020-02-07 06:25:59'),
(9, 'Christopher S. Keating', '2020-03-09 06:10:57'),
(10, 'Ralph H. Vocque', '2020-03-09 06:10:57'),
(11, 'Jose A Cruz Gonzalez', '2020-03-09 06:11:39'),
(12, 'Farhana Khan', '2020-03-09 06:11:39'),
(13, 'Monica C Burgos Garcia', '2020-03-09 06:12:13'),
(14, 'Arsen Karapetyan', '2020-03-09 06:12:13'),
(15, 'Rumany C. Penn', '2020-03-09 06:12:41'),
(16, 'Justin A. Boyd', '2020-03-09 06:12:41'),
(17, 'Thomas J Arista', '2020-03-09 06:13:03'),
(18, 'Rita K Kabaso', '2020-03-09 06:13:03'),
(19, 'Zhao Wang', '2020-03-09 06:14:15'),
(20, 'Linda F. Murphy', '2020-03-09 06:14:15'),
(21, 'Jose E. Melendez', '2020-03-09 06:14:47'),
(22, 'Walden H. Lee', '2020-03-09 06:14:47'),
(24, 'Michael R. Shanks', '2020-03-09 06:15:31'),
(25, 'Diane Raccasi', '2020-03-09 06:17:23'),
(26, 'Kellia N. Hicks', '2020-03-09 06:17:23'),
(27, 'Dongping Dai', '2020-03-09 06:18:01'),
(28, 'Gayle S. Lawson', '2020-03-09 06:18:01'),
(29, 'Kenneth H. Williams', '2020-03-16 06:25:10'),
(30, 'Michael A. Charles', '2020-03-16 06:25:42'),
(31, 'June P. Page', '2020-03-16 06:25:42'),
(33, 'Rajiv R. Srivastava', '2020-03-16 06:50:17'),
(34, 'Tamil Arasu', '2020-03-16 06:50:32'),
(35, 'Emmanuel J. Ramos', '2020-03-16 06:50:32'),
(36, 'Pratik S. Upadhyay', '2020-03-16 06:51:40'),
(37, 'Bijoy Panicker', '2020-03-16 06:51:40'),
(39, 'Kejun Cheng', '2020-03-16 06:52:43'),
(41, 'Laura Fontan', '2020-03-16 06:53:12'),
(42, 'Laurie Nelson', '2020-03-16 06:53:33'),
(43, 'Ademola O. Daramola', '2020-03-16 06:53:33'),
(44, 'Anastasia M. Shields', '2020-03-16 06:55:01'),
(45, 'Carrie A. Hughes', '2020-03-16 06:55:01'),
(46, 'Patric C. Klotzbuecher\r\n', '2020-06-30 12:01:33'),
(47, 'Yasamin Ameri\r\n', '2020-07-01 06:39:25'),
(48, 'Jessica L. Pressley\r\n', '2020-07-01 07:35:29'),
(49, 'Scott T. Ballard', '2020-07-01 08:18:41'),
(50, 'Parul M. Patel', '2020-07-01 08:18:58'),
(51, 'Dipesh K. Shah', '2020-07-01 09:58:01'),
(52, 'William Leonard', '2020-07-01 12:43:36'),
(53, 'Satheesh Thomas', '2020-07-01 13:00:09'),
(54, 'Sarah Ibrahim', '2020-07-02 05:22:51'),
(55, 'Nicole E. Knowlton', '2020-07-02 05:39:44'),
(56, 'Rebecca Dombrowski', '2020-07-02 05:40:08'),
(57, 'Pei I. Chu', '2020-07-02 05:40:26'),
(58, 'Alan P. Kurtzberg', '2020-07-02 05:56:35'),
(59, 'Junho Pak', '2020-07-02 06:03:17');

-- --------------------------------------------------------

--
-- Table structure for table `inspector_details`
--

CREATE TABLE IF NOT EXISTS `inspector_details` (
  `id` int(11) NOT NULL,
  `inspector_id` int(11) NOT NULL,
  `title` varchar(255) NOT NULL,
  `email_id` varchar(50) NOT NULL,
  `phone` varchar(20) NOT NULL,
  `address` varchar(1000) NOT NULL,
  `fb` varchar(100) NOT NULL,
  `linkdin` varchar(100) NOT NULL,
  `reference` longtext NOT NULL,
  `image` varchar(255) NOT NULL,
  `working_since` varchar(100) NOT NULL,
  `description` longtext NOT NULL,
  `country` longtext NOT NULL,
  `total_483` longtext NOT NULL,
  `type_of_obbservation` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=8 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `inspector_details`
--

INSERT INTO `inspector_details` (`id`, `inspector_id`, `title`, `email_id`, `phone`, `address`, `fb`, `linkdin`, `reference`, `image`, `working_since`, `description`, `country`, `total_483`, `type_of_obbservation`, `createdate`) VALUES
(1, 1, 'Interdisciplinary Scientist / Investigator at FDA', 'Unnee.Ranjan@fda.hhs.gov', '973-331-4963', 'River Vale, New Jersey, Parsippany NJ 07054, DO-NWJ', 'https://www.facebook.com/unnee.ranjan', 'https://www.linkedin.com/in/unneeranjan/', 'https://fdazilla.com/483s/inspectorrank/ranjan-unnee <br/>\nhttps://www.federalpay.org/employees/food-and-drug-administration/ranjan-unnee<br/>\nhttps://www.facebook.com/unnee.ranjan<br/> https://www.linkedin.com/in/unneeranjan/', 'aa.png', '2014', 'Currently working at Food and Drug Administration (FDA) as Interdisciplinary Scientist / Investigator. Licensed Pharmacist in the state of New Jersey; ASQ Certified Six Sigma Green Belt.  Over eleven (11) years of experience in Pharmaceutical Process development, Scale-up, Technology transfer, Optimization and Validation with formulation development experience.', 'United States, Belgium, Thailand, India, Taiwan, Singapore, Germany, Italy, and Australia.', '1', '1', '2020-02-14 09:47:18'),
(2, 2, 'Investigator at FDA', 'Lata.Mathew@fda.hhs.gov', '973-331-4996', 'Parsippany NJ 07054, DO-NWJ, SUITE-300', '', 'https://www.linkedin.com/in/lata-mathew-924021158/', 'https://fdazilla.com/483s/inspectorrank/mathew-lata-c<br/>\nhttps://www.federalpay.org/employees/food-and-drug-administration/mathew-lata-c', '', '2016', 'In 2018, Lata C. Mathew was a Consumer Safety Personnel at the Food and Drug Administration in Parsippany, New Jersey. Lata C. Mathew is a GS-12 under the general schedule payscale.  Lata Mathew have done more than 51 inspections in 6 countries: United States, India, Israel, Germany, Switzerland, and Spain.', 'United States, India, Israel, Germany, Switzerland, and Spain.', '1', '1', '2020-02-14 09:48:17'),
(3, 3, 'Investigator at FDA', 'Angela.Glenn@fda.hhs.gov', '407-475-4751', 'Maitland FL 32751, DO-FLA, SUITE-200', '', '', 'https://fdazilla.com/483s/inspectorrank/glenn-angela-e<br/>\nhttps://www.federalpay.org/employees/food-and-drug-administration/glenn-angela-e', '', 'Prior to 2004', ' In 2018, Angela E. Glenn was a Consumer Safety Personnel at the Food and Drug Administration in Maitland, Florida. As our dataset only goes as far back as 2004, it is likely that has worked in the federal government prior to 2004. Angela E. Glenn is a GS-13 under the general schedule payscale. Angela Glenn have done more than 213 inspections in 17 countries: Belgium, Switzerland, United States, India, Germany, Austria, Japan, France, Latvia, Ireland, Bangladesh, Malaysia, China, Italy, Spain, Portugal, and Australia.', 'Belgium, Switzerland, United States, India, Germany, Austria, Japan, France, Latvia, Ireland, Bangladesh, Malaysia, China, Italy, Spain, Portugal, and Australia.', '1', '1', '2020-02-14 09:48:48'),
(4, 4, 'Investigator at FDA', 'Cheryl.Clausen@fda.hhs.gov', '813-915-7967', 'Tampa FL 33618, RP-TMP1, SUITE-230', '', '', 'https://fdazilla.com/483s/inspectorrank/clausen-cheryl-a<br/>\nhttps://www.federalpay.org/employees/food-and-drug-administration/clausen-cheryl-a', '', '2014', 'In 2018, Cheryl A. Clausen was a Chemist at the Food and Drug Administration in Tampa, Florida. Cheryl A. Clausen is a GS-13 under the general schedule payscale. Cheryl Clausen have done more than 77 inspections in 16 countries: United States, China, Switzerland, France, Italy, United Kingdom, India, Ireland, Japan, Germany, Spain, Austria, Czech Republic, Canada, Colombia, and South Africa.', 'United States, China, Switzerland, France, Italy, United Kingdom, India, Ireland, Japan, Germany, Spain, Austria, Czech Republic, Canada, Colombia, and South Africa.', '1', '1', '2020-02-14 09:49:08'),
(5, 5, 'Investigator at FDA', 'Jogy.George@fda.hhs.gov', '973-331-4909', 'Parsippany NJ 07054, DO-NWJ, SUITE-300', '', '', 'https://fdazilla.com/483s/inspectorrank/george-jogy<br/>\nhttps://www.federalpay.org/employees/food-and-drug-administration/george-jogy', '', '2015', 'In 2016, Jogy George was a Consumer Safety Personnel at the Food and Drug Administration in Dallas, Texas. began working at the Food and Drug Administration in 2015 with a starting salary of $102,894. Since then, ''s salary has increased to $104,283 in 2016. In 2016, Jogy George was a GS-13 under the general schedule payscale.', 'United States, India, China, Mexico, Finland, and Switzerland.', '1', '1', '2020-02-14 09:49:34'),
(6, 6, 'Investigator at FDA', 'Justin.Boyd@fda.hhs.gov', '608-264-5332 x106', 'Madison WI 53715, RP-MAD, SUITE-202', '', '', 'https://fdazilla.com/483s/inspectorrank/boyd-justin-a<br/>\nhttps://www.federalpay.org/employees/food-and-drug-administration/boyd-justin-a', '', '2008', 'In 2018, Justin A. Boyd was a Consumer Safety Personnel at the Food and Drug Administration in Madison, Wisconsin. Justin A. Boyd is a GS-13 under the general schedule payscale.', 'United States, China, Portugal, Switzerland, Korea (the Republic of), Japan, India, Germany, Canada, Italy, Poland, Taiwan (Province of China), Taiwan, Belgium, United Kingdom, Sweden, Finland, Hungary, Thailand, New Zealand, Australia, and Singapore.', '1', '1', '2020-02-14 09:49:56'),
(7, 8, 'Investigator at FDA', 'Yvins.Dezan@fda.hhs.gov', '973-331-4990', 'Parsippany NJ 07054, DO-NWJ, SUITE-300', '', '', 'https://www.federalpay.org/employees/food-and-drug-administration/dezan-yvins<br/>\nhttps://fdazilla.com/483s/inspectorrank/dezan-yvins', '', '2016', '', 'United States, China, India, Netherlands, Germany, United Kingdom, Austria, Canada, Trinidad & Tobago, Bahamas, Argentina, and Korea (the Republic of).', '1', '1', '2020-02-14 09:50:16');

-- --------------------------------------------------------

--
-- Table structure for table `news`
--

CREATE TABLE IF NOT EXISTS `news` (
  `id` int(11) NOT NULL,
  `title` varchar(255) NOT NULL,
  `date` date NOT NULL,
  `short_description` longtext NOT NULL,
  `description` longtext NOT NULL,
  `image` varchar(255) NOT NULL,
  `refrence_link` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=68 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `news`
--

INSERT INTO `news` (`id`, `title`, `date`, `short_description`, `description`, `image`, `refrence_link`, `createdate`) VALUES
(1, 'Drug marketers to be held responsible for quality', '2020-02-14', 'Pharmaceutical companies that market medicines made by third parties in the country will now be held responsible for drug product quality with the health and family welfare ministry on Thursday issuing a notification to this effect.', 'New Delhi: Pharmaceutical companies that market medicines made by third parties in the country will now be held responsible for drug product quality with the health and family welfare ministry on Thursday issuing a notification to this effect. The move will impact many big domestic and multinational pharmaceutical companies that get their medicines manufactured by smaller companies.\r\n<br/>\r\nAt present, there is no liability on them for any defect in a drug. Under the Drugs and Cosmetics Rules, only the manufacturer is held responsible for spurious or substandard drug. The marketing companies just require a license to sell their drugs. Once the new rules come into effect from March 2021, the drug regulator can also penalise the marketing companies in case of spurious or substandard medicines. “Any marketer who sells or distributes any drug shall be responsible for quality of that dr ..\r\n<br/>\r\n\r\n', 'medicine-reuters.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals\r\n', '2020-03-02 06:53:53'),
(2, 'Dr Reddy''s buys Wockhardt’s India formulations business for Rs 1,850 crore', '2020-02-13', 'The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS,Dermatology, Pain and Vaccines, which would transfer to Dr Reddy''s along with related sales and marketing teams and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees.', 'MUMBAI: Dr Reddy’s Laboratories (DRL) acquired a majority of Wockhardt’s domestic formulations business for Rs 1,850 crore, underscoring the company’s commitment to the India market as it seeks to de-risk itself against regulatory pressure in the US. With this buyout, DRL is set to become the 11th largest pharmaceutical company in the Rs 14 lakh crore India market, up from 14.<br/>\r\nWockhardt has been trying to reorganise its business for months, and had pursued the idea of a stake sale as it looks to reduce debt.<br/>\r\nThe sale process had seen interest from investors including private equity firms such as Chrys Capital, KKR and PAG.', 'news2.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-02-29 08:07:40'),
(4, 'Coronavirus outbreak: Drug pricing regulator asks companies to give information on price, inventory', '2020-02-28', 'The government has been examining the impact of the shutdown in China on the pharmaceutical sector in India. The DoP has also asked the country’s drug regulatory authority, Central Drugs Standard Control Organization, to examine to what degree India depends on China for bulk drugs, possible shortages of molecules and measures that can be taken to keep the situation under control.', 'NEW DELHI: India’s drug pricing regulator has sought details of the price movement and inventory of 58 key ingredients that go into the making of finished drug dosages, seeking to ensure that the Covid-19 outbreak doesn’t cause the Chinese-dependent supply chain to snap and result in an undue rise in retail prices of medicines locally.<br/>\r\nThe regulator has told drugmakers and industry groupings to submit the price movement, production details and inventory of active pharmaceutical ingredients (APIs) and key starting material (KSM) of 58 crucial APIs that are imported from China.<br/>\r\nThe APIs are used in antibiotics, vitamins and other essential medicines, and are heavily sourced from China. These APIs are paracetamol, aspirin, azithromycin, amoxicillin, ofloxacin, metronidazole; vitamins such as B12, B1, B6, and E; female hormone progesterone; HIV drugs lopinavir and ritonavir; and blood pressure-controlling drug valsartan.\r\n', '1.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/', '2020-03-05 05:34:03'),
(5, 'Potential for growth in ecommerce, pharmacy: Reckitt Benckiser global CEO', '2020-02-29', 'RB global chief executive Laxman Narasimhan said, “We have created a clear roadmap of growth for each space that leads up to a company that grows in midsingle digits… for example, in urbanising and developing India.”', 'NEW DELHI: Ecommerce and pharmacy channels are clear growth channels in India and similar markets, according to UK healthcare and consumer goods maker Reckitt Benckiser.</br>\r\nAt a post-earnings analyst call on Friday, RB global chief executive Laxman Narasimhan said, “We have created a clear roadmap of growth for each space that leads up to a company that grows in midsingle digits… for example, in urbanising and developing India.</br>\r\nReferring to its mainstay hygiene brands in India such as Dettol and Harpic, the chief executive said, “Penetration rates in urban environments have gone up by 20% and in rural communities by over 10%. But both brands still have lots of headroom.”\r\n', 'reckitt-ceo.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 05:53:10'),
(6, 'Sun Pharma flags hypertension drug shortage due to supply constraint', '2020-03-02', 'The company said it does not source the active pharmaceutical ingredients (API) of the drug from China, adding that supply of some other APIs was impacted by the coronavirus', 'Sun PharmaceuticalNSE 0.76 % Industries Ltd said on Monday there was a shortage of its generic version of hypertension drug pindolol due to unavailability of supply of the drug''s ingredients.</br/>\r\nThe company said it does not source the active pharmaceutical ingredients (API) of the drug from China, adding that supply of some other APIs was impacted by the coronavirus.</br>\r\n"We have sufficient inventory of API and raw materials for the short term," Sun Pharma said in an email.', 'sunpharma.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 05:56:10'),
(7, 'Sun Pharma flags hypertension drug shortage', '2020-03-02', 'Indian companies are the main supplier of generic drugs to the world and procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China. The coronavirus outbreak has disrupted international businesses dependent on Chinese supplies and industry experts expect Indian generic drugmakers to face supply shortages from China if epidemic drags on.', 'BENGALURU: Indian drugmaker Sun Pharmaceutical Industries Ltd reported a shortage of its generic version of hypertension drug pindolol in the United States due to a lack of pharmaceutical ingredients, but said the shortfall did not stem from China.<br/>\r\nIndian companies are the main supplier of generic drugs to the world and procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China.<br/>\r\nThe coronavirus outbreak has disrupted international businesses dependent on Chinese supplies and industry experts expect Indian generic drugmakers to face supply shortages from China if the epidemic drags on.<br/>\r\n"At the moment, we haven''t seen any major disruption in API supplies due to the coronavirus outbreak in China," Sun PharmaNSE 0.72 % said in an email on Monday, without giving details on the reasons for the shortfall in pindolol ingredients.\r\n', 'pharma-getty.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 05:59:40'),
(8, 'Covid-19 impact: Government panel lists essential drugs that can run out', '2020-03-03', 'A high-level government committee, which submitted its report to the Department of Pharmaceuticals (DoP) last week, reviewed 54 drugs and said that out of these, 34 have no alternative. Out of the 54, it classified 32 as critical and essential, 15 as noncritical and essential and seven drugs as essential.', 'NEW DELHI: A government committee has identified various essential drugs including key antibiotics such as amoxicillin, moxifloxacin, doxycycline and tuberculosis (TB) drug rifampicin that could run out as supplies of bulk raw materials from China have been disrupted because of Covid-19 outbreak.<br/>\r\nA high-level government committee, which submitted its report to the Department of Pharmaceuticals (DoP) last week, reviewed 54 drugs and said that out of these, 34 have no alternative.ET has seen the report.</br>\r\nOut of the 54, it classified 32 as critical and essential, 15 as noncritical and essential and seven drugs as essential.\r\n', '2.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 06:03:17'),
(9, 'Setting up pharma R&D bases in India will soon be incentivised', '2020-03-03', 'Government seeks feedback from top pharmaceutical companies as it considers making regulatory changes to offer specific tax sops for specialised research in certain categories.', 'Mumbai: The government plans to ring in regulatory changes to give more tax and other incentives to pharmaceutical companies that set up research and development (R&D) base in India.<br/>\r\nThe government has reached out to some of the top pharma companies and sought feedback on the kind of tax sops and other boosters for R&D investment in India.<br/>\r\nIndustry trackers said the government could be giving out specific tax sops for specialised research in certain categories, and is analysing how tax sops could impact the sector and future tax revenues.<br/>\r\nIndustry experts said the cost of arriving at healthcare innovation and the efforts required are very high due to the unpredictability of the outcomes of clinical trials.\r\n', 'pharma-ap.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 06:08:33'),
(10, 'Incentives scheme on cards to give impetus to API manufacturing', '2020-03-04', 'The Department of Pharmaceuticals (DoP) has proposed creation of a corpus fund of Rs 3,000 crore for companies that are interested in setting up API or fermentation units in India, people in the know told ET.', 'New Delhi: The government is working on an incentive scheme to boost domestic manufacturing of active pharmaceutical ingredients (APIs), as it fears supply disruptions owing to the coronavirus outbreak.<br/>\r\nThe Department of Pharmaceuticals (DoP) has proposed creation of a corpus fund of Rs 3,000 crore for companies that are interested in setting up API or fermentation units in India, people in the know told ET.<br/>\r\nDoP has formulated an incentive-based scheme in consultation with the government’s think tank Niti Aayog and is likely to seek cabinet approval soon, said the people.\r\n', 'drug-getty.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 06:15:50'),
(11, 'How long will India''s coronavirus medicines hold out? Here''s the latest data', '2020-03-05', 'A committee formed by the government has assured that India need not worry about drug shortages. The committee, in its report, has said that the present stock-in hand of the Active Pharmaceutical Ingredients (APIs) may be sufficient for 2 to 3 months to manufacture formulations.', 'A committee formed by the government has assured that India need not worry about drug shortages for some time to come. The committee, in its report, has said that the present stock-in-hand of the Active Pharmaceutical Ingredients (APIs) may be sufficient for 2 to 3 months to manufacture formulations.<br/>\r\nYesterday, after a meeting at the Department of Pharmaceuticals, India restricted export of about 26 APIs and formulations including antibiotics, vitamins and hormones — with immediate effect, as the government explores measures to ensure there is no shortage of drugs in India due to the lockdown in China’s Hubei’s province, the epicentre of the coronavirus outbreak and also a major source of raw material or APIs.<br/>\r\nChina accounted for 67.56 per cent of India''s total imports of bulk drugs and drug intermediates at $2,405.42 million in 2018-19.\r\n', 'pills-.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-05 06:19:49'),
(12, 'Covid-19: Pharma companies ask Govt to lift API''s export restrictions', '2020-03-10', 'Pharmaceutical lobby groups have urged the government to lift restrictions on export of active pharmaceutical ingredients (APIs) and formulations, saying they have enough stock and there will be no shortage of these formulations in India amid the coronavirus outbreak.', 'NEW DELHI: Pharmaceutical lobby groups have urged the government to lift restrictions on export of active pharmaceutical ingredients (APIs) and formulations, saying they have enough stock and there will be no shortage of these formulations in India amid the coronavirus outbreak.\r\n\r\nThe government had put a restriction on export of several antibiotics, hormones and vitamins, anticipating shortage of these medicines as the coronavirus infection spreads globally.\r\n\r\nThe Indian Pharmaceutical Alliance (IPA), which represents the country’s biggest drug makers, and the Indian Drugs’ Manufacturer''s Association (IDMA) have written to the government seeking withdrawal of that notification as, according to them, they have surplus to meet the global demand and such a restriction would adversely affect their image. “In case of any shortages developing unexpectedly, all production and sale of APIs and formulations will be restricted to domestic consumption only,” sai ..\r\n', 'mkk.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/', '2020-03-16 04:57:38'),
(13, 'Biocon, Mylan win US court ruling in favour of insulin Glargine', '2020-03-11', 'US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insulin Glargine product ‘not infringed’ and ‘invalid’ for lack of written description, said Biocon in a press statement. Semglee is co-developed with Mylan in the US.', 'Bengaluru: BioconNSE -2.01 %, with its partner Mylan, has won a US court ruling that invalidated rival SanofiNSE -2.98 %’s patent on the insulin Glargine device, removing a key legal hurdle for the biotech major to commercialize Semglee.\r\n\r\nThe US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insulin Glargine product ‘not infringed’ and ‘invalid’ for lack of written description, said Biocon in a press stat ..\r\nIn October 2017, Sanofi had initiated patent infringement litigation against Biocon and Mylan’s NDA in the US District Court of New Jersey that included the formulation patents covering insulin Glargine as well as patent covering the Insulin Glargine injection pen, triggering a 30-month stay on the product’s approval.', 'court1_bccl.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-16 05:02:03'),
(14, 'Covid-19: No near-term threat to pharma cos'' credit profile''', '2020-03-12', 'If the virus outbreak isn''t contained over the next three months, supply disruption is likely to be far greater than that in FY17, resulting in pressures on cash flows for players. But the pressure will be less on API players. Given the low degree of backward integration, the report believes half companies may face pressures on their credit metrics.', 'MUMBAI: The Covid-19 pandemic is unlikely to hit credit profiles of domestic pharma companies in the near-term, despite their heavy reliance on Chinese ingredients and intermediates, says a report.\r\n\r\nThe domestic pharma industry imports almost 70 per cent of ingredients and intermediaries from China, which is the world''s largest supplier market for the sector.\r\n\r\nBut if supply doesn''t normalise over the next three-to-nine months, pressure on credit buffers can intensify and rating t ..\r\n', 'pharma-agencies.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-16 05:04:52'),
(15, 'Covid-19: China stalls supplies, India faces anti-retroviral shortage', '2020-03-13', 'Antiretrovirals - used for treating coronavirus - are manufactured by around five major pharma companies in India. The demand for such drugs have surged, and China is holding back supplies to meet its own demand. Manufacturers said they presently have stocks to treat around one lakh patients only. China is the only supplier of these APIs to India and there is no alternative source.', 'NEW DELHI: Local drug makers are facing supply disruptions from China for some active pharmaceutical ingredients (APIs) that are used in manufacturing medicines for treating coronavirus, industry executives said.\r\n\r\nThese medicines - antiretrovirals - are manufactured by around five major pharma companies in India and are supplied to various other countries apart from local use. While in the wake of global coronavirus outbreak, the demand for such drugs have surged, China is holding back.\r\n', 'medicines.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/', '2020-03-16 05:07:24'),
(16, 'Bulk drug units may not have to assess environment impact', '2020-03-14', 'The ministry of environment and forest is contemplating putting bulk drug manufacturing units in B2 category, which would mean that their manufacturers will not be required to submit an environment impact assessment (EIA) report.', 'New Delhi: The ministry of environment and forest is contemplating putting bulk drug manufacturing units in B2 category, which would mean that their manufacturers will not be required to submit an environment impact assessment (EIA) report, people in the know told ET. The move is expected to significantly reduce time taken to get approvals and give impetus to the domestic industry.\r\n\r\nIf the project falls in B category, it goes to the state government for clearance which further categorise ..\r\n', 'medicine-reuters.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-16 05:09:35'),
(17, 'Coronavirus: HIV drugs can be used in severe cases, says ICMR', '2020-03-15', 'According to ICMR experts, the inclusion of the anti-HIV drugs for treating Covid-19 was based on earlier evidence about their effectiveness against SARS and MERS coronaviruses that led to outbreaks in different parts of the world in 2002-03 and 2012, respectively, as well as the docking studies conducted by National Institute of Virology, Pune.', 'NEW DELHI: Anti-HIV drugs, Lopinavir and Ritonavir, can be used to treat Covid-19 patients in severe cases.<br/>\r\n\r\nIndia’s top health research body, the Indian Council of Medical Research (ICMR), has suggested this in the treatment protocol for Covid-19 published by it in IJMR, a medical journal.<br/>\r\n\r\nLopinavir and Ritonavir, the protocol suggests, can be used in adults over 18 years of age who are confirmed positive for Covid-19 and have complications such as: severe respiratory distress<br/>\r\n', 'coronavirus.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-16 05:12:46'),
(18, 'Exporters line up for restricted API licence', '2020-03-16', 'The government, on March 3, restricted the exports of 26 API and formulations, including paracetamol and vitamins B1, B6 and B12 in order to ensure there is no shortage of drugs in India due to the lockdown in China’s Hubei’s province, the epicentre of the coronavirus outbreak, and a major source of these raw materials.', 'NEW DELHI: Exporters have lined up applications seeking licence to ship restricted Active Pharmaceutical Ingredients or APIs. The government has received as many as 200 applications from pharma firms in a span of 10 days after it tightened their export norms.<br/>\r\n“We have received about 200 licence applications. We will examine them,” said an official in the know of the development.<br/>\r\nThe government, on March 3, restricted the exports of 26 API and formulations, including paracetamol and vitamins B1, B6 and B12 in order to ensure there is no shortage of drugs in India due to the lockdown in China’s Hubei’s province, the epicentre of the coronavirus outbreak, and a major source of these raw materials.\r\n', 'pharma.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-03-16 05:15:52'),
(19, 'Biocon, Mylan launch cancer drug in Canada', '2020-04-28', 'Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in July 2018.', 'Biocon and Mylan NV have jointly launched Fulphila, a biosimilar to Neulasta (pegfilgrastim), in Canada for cancer patients.\r\n<br/>\r\nFulphila, which was launched in Australia two weeks ago, is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, said Biocon in a press release.\r\n<br/>\r\nFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in July 2018.\r\n<br/>\r\n“We are pleased to expand access to our high quality biosimilar pegfilgrastim to patients in Canada. This is the second biosimilar from our portfolio to be launched in Canada by our partner Mylan and is an endorsement of our science, development and manufacturing capabilities in the area of biologics. We are committed to serve 5 million patients through our biosimilars portfolio and cross a revenue milestone of $1 billion by FY22,” said Christiane Hamacher, CEO of Biocon Biologics, a subsidiary.', 'drugs.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 06:45:16'),
(20, ' Home Industry Auto Banking/Finance Cons. Products Energy Ind''l Goods/Svs Healthcare/Biotech Services More BiotechHealthcarePharmaceuticals Business News›Industry›Healthcare/Biotech›Pharmaceuticals›Glenmark pharma starts clinical trial on antiviral Favipi', '2020-04-30', 'The drug sold under brand name Avigan by Fujifilm Toyama Chemical has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.', 'Glenmark PharmaceuticalsNSE -0.73 % on Thursday said that it has received the Indian drug controller''s approval to conduct clinical trial on Favipiravir , the antiviral drug that is being used in the treatment of Covid-19 in few countries. The drug sold under brand name Avigan by Fujifilm Toyama Chemical has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.\r\n<br/>\r\nFujifilm too has started phase 3 trial on this drug and also increased its production. Glenmark''s announcement comes at a time when another Indian company, Strides Pharma said that it has already started shipping the drug to countries in the gulf region.\r\n<br/>\r\n"Having internally developed the API and the formulations for the product, Glenmark filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients", the company said in a statement. Adding that it is the first pharmaceutical company in India to be given an approval by the regulator to start the trial on COVID-19 patients in India.\r\n<br/>\r\nAs per the clinical trial protocol approved, 150 subjects with mild to moderate COVID-19 will be randomized in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care. Treatment duration is a maximum of 14 days and the total study duration will be maximum for 28 days from randomization.', 'corona-afp.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 06:52:50'),
(21, 'Drug companies offer perks to get staff back to work', '2020-05-01', 'India’s drug companies that come under essential services are handing out incentives and assurance of a sterile work environment to workers, to motivate them to get to work in the wake of the Covid-19 pandemic.', 'MUMBAI: India’s drug companies that come under essential services are handing out incentives and assurance of a sterile work environment to workers, to motivate them to get to work in the wake of the Covid-19 pandemic.\r\n<br/>\r\nIncreased export as well as domestic demand for drugs such as hydroxychloroquine and chronic therapy medications has led to their manufacturers keeping their production lines running. The biggest challenges for them are over logistics and getting employees to work.\r\n<br/>\r\nLaurus is incentivising employers to come to work. This includes additional wages, transportation facilities like private buses where physical distancing can be practised and assuring the workforce that they will be working in a safe environment. “We are giving confidence to our employees that we are maintaining sanitation to the highest standards. If our colleagues do not have confidence to come to workplace, they won’t come,” Chava said.\r\n<br/>\r\nThe company has put in place a protocol of health screening, which includes thermal check-ups and a questionnaire for employees about their health, across its corporate office as well as manufacturing facilities.\r\n', '4-afp.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/', '2020-05-09 06:58:41'),
(22, 'Looking at ''repurposing'' drugs: Biocon', '2020-05-02', 'We are working to repurpose our novel monoclonal antibody Itolizumab (used in psoriasis) to treat complications caused by Covid-19 infection. If we can successfully establish the potential role for our molecule in treating Covid-19 complications, it will enable us to address a critical unmet need, Kiran Mazumdar-Shaw said.', 'Bengaluru-based biotech major BioconNSE 2.72 % is working on multiple fronts — therapeutic vaccines, new drugs and ‘repurposing’ medicines — to tackle the Covid-19 pandemic. The company, with revenues of over Rs 5,600 crore, hopes to “repurpose” its existing novel biologic Itolizumab to treat complications caused by Covid-19, while another drug Cytosorb, used for sepsis treatment, may also help in reducing mortality, its chairperson Kiran Mazumdar-Shaw said. Biocon is exploring opportunities to  ..\r\n<br/>\r\nWe are working to repurpose our novel monoclonal antibody Itolizumab (used in psoriasis) to treat complications caused by Covid-19 infection. If we can successfully establish the potential role for our molecule in treating Covid-19 complications, it will enable us to address a critical unmet need.\r\n<br/>\r\nIn addition, Cytosorb, a product that Biocon has licensed from a US company, has recently been approved by the USFDA for emergency treatment of Covid-19. Cytosorb — introduced in India for sepsis treatment in 2013 — is a safe and well-tolerated innovative therapy for managing cytokine storm in critically-ill patients. We hope that it will help in bringing down mortality in Covid-19 patients as well.\r\n', 'kiran-mazumdar-shaw-bccl.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 08:51:15'),
(23, 'Enough medicine stocks available, avoid panic buying: AICDA', '2020-05-02', '"In all 8.50 lakh chemist shops in the country, all kinds of medicines are available. People should not indulge in panic buying or hoard medicines out of fear. Purchase should be made on doctor''s prescription," said All India Chemists and Druggists Association president Jagannath Shinde.', '	Thane: There is sufficient stock of medicines in the country and people should not indulge in panic buying amid the coronavirus outbreak, said All India Chemists and Druggists Association president Jagannath Shinde on Sunday. Talking to reporters in Kalyan here, Shinde said current stocks would easily last till July and fresh supply from pharmaceutical companies was coming in regularly.\r\n	<br/>\r\n	"In all 8.50 lakh chemist shops in the country, all kinds of medicines are available. People should not indulge in panic buying or hoard medicines out of fear. Purchase should be made on doctor''s prescription," he said.', '1.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 08:53:16'),
(24, 'Remdesivir expected to be available for COVID-19 patients from next week: top company official', '2020-05-04', 'The Food and Drug Administration (FDA) gave emergency use authorisation (EUA) for the use of investigational Remdesivir to treat COVID-19 patients after some researches, including one led by Indian-American physician Aruna Subramanian, found that the drug helped recover some of the infected cases faster.', 'HOUSTON: Antiviral drug Remdesivir, approved by the US food and regulatory body for emergency use to treat the COVID-19 patients, is expected to be available by next week, the CEO of the company manufacturing the medicine has said.\r\n<br/>\r\nThe announcement was made on Sunday by Dan O''Day, CEO of Gilead Sciences, the pharmaceutical company making the vaccine.\r\n<br/>\r\nThe announcement was made on Sunday by Dan O''Day, CEO of Gilead Sciences, the pharmaceutical company making the vaccine.\r\n<br/>\r\nThe US is the worst-affected country in the world with over 1.1 million COVID-19 cases and more than 67,000 deaths, according to the Johns Hopkins University data.\r\n<br/>\r\nThe Food and Drug Administration (FDA) gave emergency use authorisation (EUA) for the use of investigational Remdesivir to treat COVID-19 patients after some researches, including one led by Indian-American physician Aruna Subramanian, found that the drug helped recover some of the infected cases faster.\r\n', 'remdesivir.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 08:57:29'),
(25, 'Remdesivir expected to be available for COVID-19 patients from next week: top company official', '2020-05-04', 'The Food and Drug Administration (FDA) gave emergency use authorisation (EUA) for the use of investigational Remdesivir to treat COVID-19 patients after some researches, including one led by Indian-American physician Aruna Subramanian, found that the drug helped recover some of the infected cases faster.', 'HOUSTON: Antiviral drug Remdesivir, approved by the US food and regulatory body for emergency use to treat the COVID-19 patients, is expected to be available by next week, the CEO of the company manufacturing the medicine has said.\r\n<br/>\r\nThe announcement was made on Sunday by Dan O''Day, CEO of Gilead Sciences, the pharmaceutical company making the vaccine.\r\n<br/>\r\nThe announcement was made on Sunday by Dan O''Day, CEO of Gilead Sciences, the pharmaceutical company making the vaccine.\r\n<br/>\r\nThe US is the worst-affected country in the world with over 1.1 million COVID-19 cases and more than 67,000 deaths, according to the Johns Hopkins University data.\r\n<br/>\r\nThe Food and Drug Administration (FDA) gave emergency use authorisation (EUA) for the use of investigational Remdesivir to treat COVID-19 patients after some researches, including one led by Indian-American physician Aruna Subramanian, found that the drug helped recover some of the infected cases faster.\r\n', 'remdesivir.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 08:57:29'),
(26, 'Management allowed to visit pharma plants in Baddi once a week', '2020-05-05', 'The district magistrate of Solan issued an order on Sunday allowing the visits of senior management personnel once a week, albeit with caveats. Companies with names starting from A-D will be permitted such visits on Mondays, those from E-H will be allowed visits on Tuesdays, and so on through the week.', 'NEW DELHI: Managing directors and other senior executives of pharmaceutical units located in Baddi will now be able to visit the plants as Asia’s largest pharma hub located in Himachal Pradesh looks to resume operations to full capacity after it had to curtail operations upon being declared a containment zone.\r\n<br/>\r\nThe district magistrate of Solan issued an order on Sunday allowing the visits of senior management personnel once a week, albeit with caveats. Companies with names starting from A-D will be permitted such visits on Mondays, those from E-H will be allowed visits on Tuesdays, and so on through the week.\r\n<br/>\r\nAs reported by ET earlier, 50 pharmaceutical manufacturing units had to suspend their operations in Baddi while others had to significantly scale down their operations after the region was declared a containment zone, raising concerns about the shortage of medicines in the country.\r\n', 'corona-baddi.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 09:00:53'),
(27, 'Four PE firms close in on JB Chemicals', '2020-05-06', 'Four global funds have submitted non-binding bids of ?4,800-5,000 crore valuation. Final bids are likely to be in by June-end. The company had hired investment bank Avendus to find a buyer for the promoter’s stake.', 'MUMBAI: Global buyout funds KKR, Carlyle, Apax Partners and PAG are in the race to acquire domestic pharmaceuticals firm JB Chemicals & Pharmaceuticals Ltd at a valuation of about Rs 5,000 crore, or $650 million, multiple people aware of the development said.<br/>\r\nThe proposed deal valuation is 9% higher than JB Chemicals’ current market capitalisation.\r\n<br/>\r\n\r\nIts promoters, Jyotindra Bhagawanlal Mody and family have been in talks to sell their 56% stake in the listed entity since May last year. At current market price, their stake is valued at around Rs 2,516 crore.', 'pills-getty.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 10:08:31'),
(28, 'Four PE firms close in on JB Chemicals', '2020-05-06', 'Four global funds have submitted non-binding bids of ?4,800-5,000 crore valuation. Final bids are likely to be in by June-end. The company had hired investment bank Avendus to find a buyer for the promoter’s stake.', 'MUMBAI: Global buyout funds KKR, Carlyle, Apax Partners and PAG are in the race to acquire domestic pharmaceuticals firm JB Chemicals & Pharmaceuticals Ltd at a valuation of about Rs 5,000 crore, or $650 million, multiple people aware of the development said.<br/>\r\nThe proposed deal valuation is 9% higher than JB Chemicals’ current market capitalisation.\r\n<br/>\r\n\r\nIts promoters, Jyotindra Bhagawanlal Mody and family have been in talks to sell their 56% stake in the listed entity since May last year. At current market price, their stake is valued at around Rs 2,516 crore.', 'pills-getty.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 10:08:32'),
(29, 'Bilateral deals might not be equitable for Covid-19: MPP executive director Charles Gore', '2020-05-07', 'The Medicines Patent Pool is a United Nations-backed public health organisation that helps middle- and low-income countries get access to critical drugs. MPP executive director Charles Gore told ET’s Divya Rajagopal about the organisation’s plan to ensure equitable access of Covid-19 drugs and vaccines.', 'Countries are waiting for drugs and vaccines to combat Covid-19, which will help them to lift lockdowns and have treatments ready to handle future infection waves. However, access and affordability of such drugs remain a key area of concern. The Medicines Patent Pool is a United Nations-backed public health organisation that helps middle- and low-income countries get access to critical drugs. MPP executive director Charles Gore told ET about the organisation’s plan to ensure equequitable access of Covid-19 drugs and vaccines. Edited excerpts:\r\n<br/>\r\nWhich are the companies you are negotiating for Covid-19 patents?<br/>\r\nWe are in discussions with Gilead for Remdesivir. I don’t know how this will go, but we are in discussions. We have a confidentiality agreement with them, so can’t share much, but this is the first of the drugs that we are looking at. Besides this, we are watching a few drugs like Favipiravir, Tocilizumab, Sarilumab, Ruxolitinib and Siltuximab.<br/>\r\n<br/>\r\nWhat about vaccines?<br/>\r\nWe are reaching out to GSK-Sanofi, J&J (Janssen), Oxford University and the University of Bern, asking them if we can be of assistance to them – we will see how this goes. But there are several issues here. One is how much they want us to come – it is possible they might want to do it themselves. The difference here is that in a normal situation, companies might say there are 60 countries where we can make money. But here, I hope companies do not try to make money, at least not when the public health emergency is on. So, we can offer these companies management in a lot of the work involved in helping to scale up and making sure the capacity is there.\r\n', 'charles-gore-mpp-bccl.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 10:12:20'),
(30, 'Indian pharma exports miss target, stand at $20.58 bn in FY'' 20', '2020-05-08', '??Though the exports started doing well in 2019-20 and it has been a good year for the first three quarters with cumulative growth rate of 11.5 per cent during April-December 2019, the growth rate in February and March has gone down recording 7.7 per cent and -23.24 per cent respectively, resulting in the negative growth of - 2.97 per cent in the fourth quarter.\r\n', 'Hyderabad: The Indian pharmaceutical sector has been affected by the COVID-19 lockdown as exports have registered $20.58 billion during the 2019-20 financial year as against the targeted $22 billion in the previous fiscal. Despite this, there was 7.57 per cent overall growth in exports in FY ''20 over 2018-19, a press release from the Pharmaceuticals Export Promotion Council, a body under the Ministry of Commerce, said on Friday.\r\n<br/>\r\n\r\nThough the exports started doing well in 2019-20 and it has been a good year for the first three quarters with cumulative growth rate of 11.5 per cent during April-December 2019, the growth rate in February and March has gone down recording 7.7 per cent and -23.24 per cent respectively, resulting in the negative growth of - 2.97 per cent in the fourth quarter, the release said.\r\n<br/>\r\n\r\nDrug formulations and biologicals, contributing to almost 72 per cent of exports, have shown 9.5 per cent growth in FY 2020.\r\n', 'pharma.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 10:15:49'),
(31, 'Chinese drugmaker in talks to test virus vaccine globally', '2020-05-09', 'With China having largely curbed its growth of new infections, its drugmakers will need to seek international cooperation to test their vaccine candidates in other countries — a task that may be complicated by tensions between China and some nations, especially the US, over how and where the virus originated.', 'The drugmaker behind one of China’s most promising coronavirus vaccine candidates is in talks to conduct late-stage trials globally as the race for immunization against Covid-19 intensifies. Beijing-based Sinovac Biotech is in discussion with regulators in other countries, and the World Health Organization, to launch phase III clinical trials in regions where the novel coronavirus is still spreading rapidly, CEO Yin Weidong said in an interview on Thursday.\r\n<br/>\r\n“To evaluate whether the vaccine can give protection, we need to study the relation between disease incidence and vaccination,” Yin said. “You can’t do that when there’s no cases.”\r\n<br/>\r\nWith China having largely curbed its growth of new infections, its drugmakers will need to seek international cooperation to test their vaccine candidates in other countries — a task that may be complicated by tensions between China and some nations, especially the US, over how and where the virus originated.', 'vaccine-agencies.webp', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals', '2020-05-09 10:18:00'),
(32, 'Biocon''s partner Mylan gets favourable ruling from US patent authority for 4 devices', '2020-06-01', '"We are extremely pleased with the US PTAB''s ruling in favour of our partner Mylan for four device patents of Sanofi''s Lantus SoloSTAR. This strengthens our resolve to provide a high quality affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system," Biocon Biologics CEO and MD Christiane Hamacher said.', 'New Delhi: Biotechnology major Biocon on Monday said the US patent authority has ruled in favour of its partner Mylan for four device patents of Sanofi''s Lantus SoloSTAR. The favourable ruling in inter-parts review proceedings by the Patent and Trademark Appeal Board (PTAB) would pave the way for launch of insulin product Glargine in the US, Biocon said in a filing to BSE.\r\n<br/>\r\n"We are extremely pleased with the US PTAB''s ruling in favour of our partner Mylan for four device patents of Sanofi''s Lantus SoloSTAR. This strengthens our resolve to provide a high quality affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system," Biocon Biologics CEO and MD Christiane Hamacher said.\r\n<br/>\r\nA new drug application (NDA) of Biocon''s partner for Semglee is under active review by the USFDA and this favourable ruling further clears the path for the anticipated launch of our Glargine in the US in mid-CY2020, she added.\r\n<br/>\r\nThe Patent and Trademark Appeal Board found all challenged claims of Sanofi''s Lantus SoloSTAR device patents -- US Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable in inter-partes review (IPR) proceedings, Biocon said.\r\n<br/>\r\n\r\n', 'biocon-afp.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocons-partner-mylan-gets-favourable-ruling-from-us-patent-authority-for-4-devices/articleshow/76133978.cms', '2020-07-07 10:50:08'),
(33, 'Local Pharma API companies to gain from Rs 10,000 crore scheme ', '2020-06-02', 'The incentive — part of a .`10,000-crore production-linked incentive scheme to boost domestic manufacturing of critical bulk drugs and APIs approved by the Cabinet in March — will be given to companies investing on greenfield plants to manufacture 53 crucial APIs.\r\n', 'New Delhi: The government will provide an incentive of Rs 10 crore each to domestic companies setting up plants to produce 53 crucial active pharmaceutical ingredients (APIs) for which the domestic drug industry is vulnerably dependent on imports from China.\r\n<br/>\r\nThe incentive — part of a Rs 10,000-crore production-linked incentive scheme to boost domestic manufacturing of critical bulk drugs and APIs approved by the Cabinet in March — will be given to companies investing on greenfield plants to manufacture 53 crucial APIs of anti-TB drugs, steroids, vitamins, etc, with the rider that they must supply to domestic drug makers.\r\n<br/>\r\n“The scheme is applicable for domestic consumption only,” a government official told ET on condition of anonymity.\r\n<br/>\r\nThe scheme also proposes annual incentive of Rs 720 crore for crucial fermentation products including penicillin G (used to manufacture antibiotics), amino cephalosporanic acid 7-ACA (used in manufacturing antimicrobial drugs), clavulanic acid (to treat bacterial infections), and erythromycin thiocynate (antiinfectives), said the official .\r\n<br/>\r\n', 'pharma2.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/local-api-cos-to-gain-from-10kcr-scheme/articleshow/76143490.cms', '2020-07-07 11:11:04'),
(34, 'Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe', '2020-06-03', 'Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.\r\n\r\n', 'New Delhi: Pharma major Lupin on Wednesday said it has inked distribution agreements with three companies to make its drug NaMuscla commercially available in select European countries. Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.\r\n<br/>\r\nAs per the pact, Exeltis will commercialise the orphan drug in Spain and Portugal, Cresco in the Netherlands and Macure in the Nordic countries, it added.\r\n<br/>\r\nBesides, Lupin will continue commercialisation of the drug in Germany and the UK and will launch the product in Austria and France later this year.\r\n<br/>\r\n"These distribution agreements represent an important milestone for the company as we roll out commercialisation of NaMuscla across Europe," Lupin President EMEA Thierry Volle said.\r\n<br/>\r\n', 'lupin.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-inks-distribution-pact-with-3-firms-to-commercialise-namuscla-in-europe/articleshow/76171829.cms', '2020-07-07 11:24:37'),
(35, 'Eight global pharmaceutical firms evince interest in India''s plan to ramp up API production: Mansukh Mandaviya ', '2020-06-04', 'The government has also begun an exercise to assign specific tariff code to every chemical to keep a check on imports, minister of state for chemicals and fertilizers Mansukh Mandaviya told ET.', 'NEW DELHI: India''s plan to draw foreign majors to ramp up production of active pharmaceutical ingredients (APIs) has drawn interest from eight companies as it mulls extending sops to existing domestic entities as well to reduce dependence on China.\r\n<br/>\r\nThe government has also begun an exercise to assign specific tariff code to every chemical to keep a check on imports, minister of state for chemicals and fertilizers\r\n<br/>\r\nThe government would in a fortnight roll out the framework for the production linked subsidy scheme that was announced in March this year.\r\n<br/>\r\n"Eight foreign companies have evinced interest in investing in the last one month," Mandaviya said. "We are making rules and regulations for the scheme, it will be formulated in 15 days."\r\n<br/>', '31.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/eight-global-pharmaceutical-firms-evince-interest-in-indias-plan-to-ramp-up-api-production-mansukh-mandaviya/articleshow/76201809.cms', '2020-07-07 11:43:53'),
(36, 'Sun Pharma testing plant-based drug as potential COVID-19 treatment ', '2020-06-05', 'Drugmakers around the world are rushing to develop a treatment or vaccine for the fast-spreading novel coronavirus that has killed over 390,000 people and ravaged financial markets. Two other Indian companies, Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd, are also conducting trials in India for potential COVID-19 treatments.', 'BENGALURU - Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October.\r\n<br/>\r\nAQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties.\r\n<br/>\r\nThe company said the trial will be conducted across 12 centers in India in 210 patients and a human safety study of the drug has been completed.\r\n<br/>\r\n"AQCH, which is being developed for dengue, has shown broad antiviral effect in in-vitro studies and hence is being tested as a potential treatment option for COVID-19," the company said in a statement https://reut.rs/2zan0YU.\r\n<br/>\r\nDrugmakers around the world are rushing to develop a treatment or vaccine for the fast-spreading novel coronavirus that has killed over 390,000 people and ravaged financial markets.\r\n<br/>', 'untitled-39.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-testing-plant-based-drug-as-potential-covid-19-treatment/articleshow/76212572.cms', '2020-07-07 13:04:29');
INSERT INTO `news` (`id`, `title`, `date`, `short_description`, `description`, `image`, `refrence_link`, `createdate`) VALUES
(37, 'COVID-19: Infections rise, so do vaccine trials', '2020-06-06', 'Ever since the Covid-19 outbreak late last year, the world has been moving much faster with regards to working on a vaccine and a possible cure for Covid-19.', 'Ever since the Covid-19 outbreak late last year, the world has been moving much faster with regards to working on a vaccine and a possible cure for Covid-19. In India and around the world, too, drug companies have launched clinical trials that could potentially save lives of critically-ill patients and also aid in faster recovery of the moderately sick. ET reports on the new potential treatments for the virus.\r\n<br/>\r\nSUN PHARMA\r\nSun Pharma on Friday said that it has started phase-II clinical trials on a plant-based drug AQCH. The drug, which is being developed for dengue, has shown broad antiviral effects in lab studies and hence the company is hopeful that this be a potential treatment for Covid. The trial will take place across 12 centres in India and cover 210 patients. The treatment duration will be 10 days. Sun said the results of the trial are expected by October 2020. This is the second drug for which Sun has initiated trials. Last week, it had announced that it received approval to start trials on Nafamostat for Covid treatment.\r\n<br/>', 'hcq-ap.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covid-19-infections-rise-so-do-vaccine-trials/articleshow/76227030.cms', '2020-07-07 13:13:09'),
(38, 'AstraZeneca approaches Gilead about potential merger  ', '2020-06-07', 'AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger.', 'AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.\r\n<br/>\r\nThe U.K.-based firm contacted Gilead last month about a possible tie-up, the people said, asking not to be identified because the details are private. AstraZeneca didn’t specify terms for any transaction, they said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed and the companies aren’t in formal talks, the people added.\r\n<br/>\r\nAstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that’s received U.S. approval for use with coronavirus patients.\r\n<br/>', 'untitled-design-18.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-approaches-gilead-about-potential-merger/articleshow/76243855.cms', '2020-07-07 13:18:25'),
(39, 'Lupin, Marksans Pharma, Among Others Recall Various Drugs in US Market: FDA Report', '2020-07-05', 'As per the latest enforcement report, the US based-arm of Lupin is recalling 6,540 bottles of Metformin Hydrochloride extended-release tablets USP, 500 mg, due to CGMP (Current Good Manufacturing Practice) deviations.', 'Indian drug firms like Lupin, Marksans Pharma, Aurobindo Pharma and Alembic Pharmaceuticals are recalling products in the US market, as per the latest enforcement report by the US Food and Drug Administration (USFDA).\r\n<br/>\r\nWhile Lupin and Marksans Pharma are recalling diabetes drug, Aurobindo and Alembic are recalling psychiatric medication in the US market.\r\n<br/>\r\nAs per the latest enforcement report, the US based-arm of Lupin is recalling 6,540 bottles of Metformin Hydrochloride extended-release tablets USP, 500 mg, due to CGMP (Current Good Manufacturing Practice) deviations.\r\n<br/>\r\nThe drug has been manufactured at Lupin''s Goa-based manufacturing plant.\r\n<br/>\r\nFurther, Aurobindo Pharma USA Inc, a unit of Hyderabad-based Aurobindo Pharma, is recalling 1,440 bottles of Clozapine tablets in the US market.\r\n<br/>\r\nSimilarly, Alembic Pharmaceuticals is recalling 19,153 bottles of Aripiprazole tablets in the US for labelling mix up.\r\n<br/>', '1591354404_medicines_afp10.png', 'https://www.news18.com/news/world/lupin-marksans-pharma-among-others-recall-various-drugs-in-us-market-fda-report-2702313.html', '2020-07-07 13:40:47'),
(40, 'Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical', '2020-06-08', 'The company has issued voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.', 'The company has issued voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.\r\n<br/>\r\nThe recalled batch contains 11,279 bottles, it added. Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.\r\n<br/>', '1.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/marksans-pharma-recalls-11279-bottles-of-diabetes-drug-due-to-cancer-causing-chemical/articleshow/76260387.cms', '2020-07-08 06:20:57'),
(41, 'Aid organisations, varsities team up to ensure access to cheaper vaccines', '2020-06-09', 'Last week, at the Global Vaccine Summit hosted by the British government, several countries including India had committed nearly $8 billion towards a Covid-19 vaccine that would be distributed by Gavi, a not-for-profit vaccine alliance.', 'Imperial College London on Sunday announced the launch of a vaccine trial that, if successful, it plans to make available at the lowest possible cost in the UK as well as low and middle-income countries.\r\n<br/>\r\nIts researchers said the team’s supply chain and manufacturing partners will be ready to produce “tens of millions of vaccines from early 2021”.\r\n<br/>\r\nImperial College is forming a startup, VacEquity Global Health (VGH), with the backing of Hong Kong-based Chan family’s investment firm Morningstar Ventures, to carry out the trial and produce the vaccine.\r\n<br/>\r\nMédecins Sans Frontières (MSF), or Doctors Without Borders, has urged world leaders to demand pharmaceutical corporations commit to selling any potential Covid vaccines at cost.\r\n<br/>\r\n', 'vaccine-test-reuters.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aid-organisations-varsities-team-up-to-ensure-access-to-cheaper-vaccines/articleshow/76273946.cms', '2020-07-08 06:44:23'),
(42, 'Panacea Biotec joins hands with US-based Refana to develop COVID-19 vaccine', '2020-06-10', 'The company is advancing its response to address the unprecedented challenges of COVID-19 by collaborating with Refana Inc to make a vaccine widely accessible around the world in an equitable manner through a joint venture company to be based in Ireland.', 'Panacea BiotecNSE -1.81 % on Wednesday said it is setting up a joint venture firm in Ireland with US-based Refana Inc to develop a vaccine for COVID-19. The company is advancing its response to address the unprecedented challenges of COVID-19 by collaborating with Refana Inc to make a vaccine widely accessible around the world in an equitable manner through a joint venture company to be based in Ireland, Panacea Biotec said in a regulatory filing.\r\n<br/>\r\nThe collaboration aims to bring to patients a whole inactivated virus-based vaccine for COVID-19, it added. As per the partnership, Panacea Biotec will be responsible for product development and commercial manufacturing, while the JV entity undertaking clinical development and regulatory submissions across the world. Both Panacea and Refana will undertake sales and distribution of the vaccine in their respective territories, it added.\r\n<br/>\r\nThe company in partnership with Refana aims to manufacture over 500 million doses of COVID-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year, he added.\r\n<br/>', 'covid-1.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/panacea-biotec-joins-hands-with-us-based-refana-to-develop-covid-19-vaccine/articleshow/76297822.cms', '2020-07-08 06:53:49'),
(43, 'Pricing problems: Aurobindo Pharma, Sun Pharma, Lupin named in lawsuit in US', '2020-06-11', 'Attorney General Brian E Frosh in a statement issued on Wednesday said the new complaint, filed in the U.S. District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and the complaint names 26 corporate defendants and 10 individual defendants.', 'HYDERABAD: Aurobindo PharmaNSE 3.40 %, Sun PharmaNSE 1.32 % and Lupin are among the 26 drug makers facing a multi-state lawsuit filed in USA by Maryland Attorney General for alleged "conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States."\r\n<br/>\r\nAttorney General Brian E Frosh in a statement issued on Wednesday said the new complaint, filed in the U.S. District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and the complaint names 26 corporate defendants and 10 individual defendants.\r\n<br/>\r\n"This complaint shows again a tangled web of industry executives and sales people who met with each other on social outings and at trade shows, and had conversations that laid the groundwork for the illegal agreements. Their price-fixing schemes cost patients, the State of Maryland and health insurance companies billions of dollars in unnecessary health care expenditures," Frosh said.\r\n<br/>\r\nThe complaint is the third to be filed in an ongoing investigation that is possibly the largest domestic corporate cartel case in the history of the United States, the statement said.\r\n<br/>', 'pharma-bccl.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pricing-problems-aurobindo-pharma-sun-pharma-lupin-named-in-lawsuit-in-us/articleshow/76321787.cms', '2020-07-08 06:58:18'),
(44, 'India''s Zydus Cadila to make Gilead''s potential COVID-19 drug remdesivir', '2020-06-12', 'Zydus, listed as Cadila Healthcare, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero Labs Ltd in signing non-exclusive pacts with Gilead for the drug.', 'BENGALURU: Indian drugmaker ZydusNSE -0.90 % Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.\r\n<br/>\r\nZydus, listed as Cadila HealthcareNSE 0.33 %, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero Labs Ltd in signing non-exclusive pacts with Gilead for the drug.\r\n<br/>\r\nAs part of the pact, Zydus will get the manufacturing know-how from Gilead to manufacture the active pharmaceutical ingredient for remdesivir and the finished product. Zydus will market it in 127 countries, including India.\r\n<br/>', 'pharma.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-zydus-cadila-to-make-gileads-potential-covid-19-drug-remdesivir/articleshow/76345701.cms', '2020-07-08 07:08:03'),
(45, 'Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19', '2020-06-13', 'The Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm would need to do the manufacturing scale up.', 'Hyderabad: Indian generic drug maker Dr Reddy’s Laboratories announced entering into a non-exclusive licensing agreement with Gilead Sciences, which grants the Indian firm the rights to register, manufacture and sell the American biopharmaceutical firm’s investigational drug Remdesivir, a potential treatment for Covid-19.\r\n<br/>\r\nThe rights to register, manufacture and sell the drug were granted for 127 countries including India.\r\n<br/>\r\nThe Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm would need to do the manufacturing scale up.\r\n<br/>\r\n', 'drreddyy.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-inks-pact-with-gilead-to-manufacture-covid-19-drug/articleshow/76356477.cms', '2020-07-08 08:24:02'),
(46, 'Plan to approach USFDA for re-inspection of key plants in next few months: Lupin', '2020-06-14', 'The US drug regulator, after inspecting the two sites, had expressed concerns over quality-control procedures that include handling of out-of-specification results and conducting hold-time studies.', 'NEW DELHI: Drug major Lupin plans to approach the US health regulator for re-inspection of its manufacturing plants in Goa, Pithampur (Madhya Pradesh) and Somerset (US) in the next few months.\r\n<br/>\r\nThe company''s Unit 2 manufacturing plant in Pithampur, along with its Goa site, is under the US Food and Drug Administration''s (USFDA) warning letter since November 2017 for violation of current goods manufacturing practices.\r\n<br/>\r\nThe US drug regulator, after inspecting the two sites, had expressed concerns over quality-control procedures that include handling of out-of-specification results and conducting hold-time studies.\r\n<br/>\r\n', 'tablets-bccl.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/plan-to-approach-usfda-for-re-inspection-of-key-plants-in-next-few-months-lupin/articleshow/76367915.cms', '2020-07-08 08:30:19'),
(47, 'Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA region ', '2020-06-15', 'Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product supply, it added.', 'New Delhi: Drug major Sun PharmaNSE 1.20 % on Monday said it has entered into an exclusive licensing and distribution agreement with Hikma Pharmaceuticals for plaque psoriasis medicine, Ilumya, for the Middle East and North Africa (MENA) region. One of the company''s wholly-owned subsidiaries and Hikma Pharmaceuticals have entered into the agreement for Ilumya, Sun Pharma said in a filing to BSE.\r\n<br/>\r\nUnder the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product supply, it added.\r\n<br/>\r\n"Sun Pharma is eligible for upfront and milestone payments from Hikma. The term of this agreement is 15 years from first sale, with two years'' automatic renewal periods," the filing said.\r\n<br/>\r\n"Hikma''s strong presence in the MENA region will enable access to a new treatment option for people who are unable to manage their moderate-to-severe plaque psoriasis," Sun Pharma Emerging Markets Senior VP Aalok Shanghvi said.\r\n<br/>', 'sp.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-hikma-ink-exclusive-pact-for-plaque-psoriasis-drug-for-mena-region/articleshow/76382692.cms', '2020-07-08 08:37:37'),
(48, 'Alembic Pharma gets USFDA nod for generic chronic iron overload treatment tablets ', '2020-06-16', 'The company has received the final approval from the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Deferasirox tablets in the strength of 180 mg, Alembic Pharmaceuticals said in a BSE filing.', 'New Delhi: Alembic Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for generic Deferasirox tablets used for treatment of chronic iron overload in patients.\r\n<br/>\r\nThe company has received the final approval from the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Deferasirox tablets in the strength of 180 mg, Alembic Pharmaceuticals said in a BSE filing.\r\n<br/>\r\nThe company''s product is a generic version of Novartis Pharmaceuticals Corporation''s Jadenu tablets in the same strength, it added. According to IQVIA, Deferasirox tablets, 180 mg, have an estimated market size of USD 53 million for twelve months ending March 2020, Alembic Pharma said.\r\n<br/>\r\nThe tablets are indicated for treatment of chronic iron overload due to blood transfusions and also for chronic iron overload in non-transfusion-dependent thalassemia syndromes, it added.\r\n<br/>\r\n', 'pills1-thinkstock.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-generic-chronic-iron-overload-treatment-tablets/articleshow/76401337.cms', '2020-07-08 08:47:46'),
(49, 'Dexamethasone: Drug that offers hope amid surging Covid cases', '2020-06-17', 'While the world is still searching for a vaccine for Covid 19, researchers have stumbled upon a drug that has raised hopes. The drug, called dexamethasone, has reportedly given extremely welcome result during testing.', 'As per a research in the UK, dexamethasone reduced deaths by one-third in ventilated patients, and by one fifth in other patients receiving oxygen only. However, the researchers said there was no benefit from dexamethasone among the patients who did not require respiratory support.\r\n<br/>\r\nBritish Prime Minister Boris Johnson said the drug was the "biggest breakthrough yet'''' in treating the coronavirus, and top U.S. infectious disease expert Dr. Anthony Fauci called it "a significant improvement in the available therapeutic options that we have.''''\r\n<br/>\r\nMost importantly, dexamethasone is quite inexpensive. As per reports, the drug costs even less than Rs 200.\r\n<br/>', 'download.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dexamethasone-drug-that-offers-hope-amid-surging-covid-cases/a-new-hope/slideshow/76419547.cms', '2020-07-08 08:56:01'),
(50, 'Roche Pharma India expands partnership with Cipla for key oncology medicines', '2020-06-18', 'Roche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India," the company said in a statement.', 'New Delhi: Drug firm Roche Pharma India on Thursday said it has expanded its partnership with domestic pharma major CiplaNSE 0.20 % to further improve access to its key oncology medicines in India.\r\n<br/>\r\nRoche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India," the company said in a statement.\r\n<br/>\r\nThe two companies had previously entered into a similar agreement in February 2018 for promotion and distribution of tocilizumab (Actemra) and other products, it added\r\n<br/>\r\nIn similar vein, Cipla India Business Executive vice-president and CEO Nikhil Chopra said: "This (pact) represents Cipla''s unwavering commitment to address the unmet needs of cancer patients through an enhanced portfolio of offerings in this space, he added.\r\n<br/>', 'roche-reuters.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/roche-pharma-india-expands-partnership-with-cipla-for-key-oncology-medicines/articleshow/76439353.cms', '2020-07-08 08:59:25'),
(51, 'Dr Reddy''s launches generic prostate cancer treatment drug in US', '2020-06-19', 'Pharma major Dr Reddy''s Laboratories on Friday said it has launched generic Abiraterone Acetate tablets, used for treatment of prostate cancer, in the US market.\r\n', 'Pharma major Dr Reddy''s Laboratories on Friday said it has launched generic Abiraterone Acetate tablets, used for treatment of prostate cancer, in the US market. The company has launched Abiraterone Acetate tablets USP in the strength of 250 mg, after the approval from the United States Food and Drug Administration (USFDA), Dr Reddy''s Laboratories said in a filing to the BSE.\r\n<br/>\r\nThe product is a generic version of Johnson & Johnson''s Zytiga tablets, it added. According to data from IQVIA Health, Zytiga brand and generic market had US sales of around USD 454 million MAT for the 12 months ended March 2020, Dr Reddy''s Laboratories said. Shares of Dr Reddy''s Laboratories on Friday closed at Rs 4,010 per scrip on the BSE, up 0.13 per cent from its previous close.\r\n<br/>\r\n', 'nhu.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-generic-prostate-cancer-treatment-drug-in-us/articleshow/76466445.cms', '2020-07-08 09:09:08'),
(52, 'Glenmark launches COVID-19 drug after DCGI nod; MRP at Rs 103 per tablet  ', '2020-06-20', 'The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added.', 'NEW DELHI: Drug firm Glenmark PharmaceuticalsNSE 0.66 % on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet.\r\n<br/>\r\nThe drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.\r\n<br/>\r\nFabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19, it said in a statement.\r\n<br/>\r\nThe tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.\r\n<br/>\r\n', 'fabiflu.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-launches-covid-19-drug-after-dcgi-nod/articleshow/76479268.cms', '2020-07-08 09:22:41'),
(53, 'Cipla launches generic remdesivir for coronavirus patients ', '2020-06-21', 'The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of coronavirus patients.', 'New Delhi: Homegrown pharma major Cipla Ltd announced the launch of its generic version of remdesivir, which has been authorised for emergency use in treatment of COVID-19 patients by the USFDA, under its brand name Cipremi. The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of COVID-19 patients.\r\n<br/>\r\nRemdesivir is the only USFDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.\r\n<br/>\r\nCipla said it has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.\r\n<br/>\r\n"As part of a risk management plan, Cipla will provide training on use of the drug, informed patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients," the company said in a statement.\r\n<br/>', 'cipla.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-launches-generic-remdesivir-for-covid-19-patients/articleshow/76498277.cms', '2020-07-08 09:28:25'),
(54, 'Aurobindo Pharma plans to launch 50-60 products in US in FY21', '2020-06-22', 'The company has received final approval for six ANDAs (abbreviated new drug application) and launched four products in the fourth quarter of last fiscal.\r\n', 'HYDERABAD: Aurobindo PharmaNSE 2.97 % is expected to launch 50 to 60 new products during the current year, N Govindarajan, managing director of the city-based drug maker has said. "We are expecting to launch around 50 to 60 products this year including injectables...Out of the 50 to 60 products that we are talking about, 25 products have already been approved," he said during the latest earnings call earlier this month.\r\n<br/>\r\nOn a constant currency basis, itincreased by 26 per cent year-on-year to around USD 1.62 billion led by improvement in volumes and new product launches.\r\n<br/>\r\nAurobindo spent Rs 958 crore towards research and development in FY 20 which was 4.1 per cent of its total revenues.\r\n<br/>\r\nGovindarajan said the R&D spend would be 5.5 per cent of the revenues for the current year.\r\n<br/>', 'aurobindo.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-plans-to-launch-50-60-products-in-us-in-fy21/articleshow/76509828.cms', '2020-07-08 09:32:47'),
(55, 'Cipla to price remdesivir version for COVID-19 under 5,000 rupees', '2020-06-23', 'Indian pharma major Cipla Ltd and Hetero Labs gained approval to sell generic versions of remdesivir in the country. Remdesivir, intravenously administered in hospitals, is the first treatment to show improvement in COVID-19 trials.\r\n', 'BENGALURU: Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc''s antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.\r\n<br/>\r\nCipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees.\r\n<br/>\r\nRemdesivir, intravenously administered in hospitals, is the first treatment to show improvement in COVID-19 trials. It has been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan.\r\n<br/>\r\nCipla, in an e-mailed statement, did not provide details on when the treatment, called Cipremi, will be available.\r\n<br/>', 'remdesivir-reuters.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-to-price-remdesivir-version-for-covid-19-under-5000-rupees/articleshow/76531302.cms', '2020-07-08 09:36:09'),
(56, 'Hetero Healthcare set to supply its generic COVID-19 drug at Rs 5,400 per vial across India', '2020-06-24', 'The company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra, Hetero Healthcare said in a statement.', 'NEW DELHI: Hetero Healthcare on Wednesday said is set to deliver 20,000 vials of its antiviral drug Covifor (remdesivir) across the country for the treatment of COVID-19, at a maximum retail price of Rs 5,400 per vial.\r\n<br/>\r\nThe company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra, Hetero Healthcare said in a statement.\r\n<br/>\r\nOn Tuesday, pharma major Cipla said, it will price its generic version of remdesivir at less than Rs 5,000 per vial. It also said that the drug will be available in the next 8 to 10 days.\r\n<br/>\r\n"The launch of Covifor in India is a significant milestone for all of us... Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating COVID-19 cases," Hetero Healthcare MD M Srinivasa Reddy said.\r\n<br/>\r\n', 'covid.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/hetero-healthcare-set-to-supply-its-generic-covid-19-drug-at-rs-5400-per-vial-across-india/articleshow/76557041.cms', '2020-07-08 09:51:25'),
(57, 'How Trump''s hydroxychloroquine push became a boon for Ipca Laboratories  ', '2020-06-25', 'The US is still relying on Indian firms to import HCQ even after the drug fell out of favor as a Covid treatment.', 'The U.S. is still relying on Indian factories that were previously banned to import hydroxychloroquine needed by lupus and rheumatoid-arthritis patients even after the drug fell out of favor as a Covid-19 treatment.\r\n<br/>\r\nIn March, the Food and Drug Administration lifted restrictions on Ipca Laboratories LtdNSE -0.53 %. in Mumbai to allow it to export hydroxychloroquine and a similar drug, chloroquine. That happened just days after President Donald Trump touted them as potential game changers against the virus, despite a lack of clinical evidence they’d help.\r\n<br/>\r\nIpca’s factories had been banned from shipping to the U.S. since 2015 after inspectors discovered multiple violations of manufacturing standards, including manipulation of data gathered during routine quality checks.\r\n<br/>\r\nSince Trump began pushing the drugs as a virus treatment, manufacturers have donated millions of pills to a national stockpile, reserved for Covid-19 patients. About 63 million tablets of hydroxychloroquine remain in the stockpile, Stephanie Bialek, a spokeswoman for the Department of Health and Human Services stockpile division, said in an email.\r\n<br/>\r\n', 'hydroxychloroquine.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/how-trumps-hydroxychloroquine-push-became-a-boon-for-ipca/articleshow/76618984.cms', '2020-07-08 09:59:00'),
(58, 'Drug makers urge Commerce Ministry to clear stuck imports  ', '2020-06-27', 'The border clash at Galwan Valley spilled over to trade between the two countries, with growing anti-China sentiment and calls to boycott Chinese products. China''s exports to India account for 2.8% of its outbound shipments.\r\n', 'MUMBAI: Indian drug makers have asked the commerce ministry to expedite the clearance of their consignments imported from China, which are stuck at several Indian ports due to extensive checking this week following border tensions.\r\n<br/>\r\nThe commerce ministry has asked the companies to wait for a couple of days, anticipating that the issue might get resolved.\r\n<br/>\r\nCustoms officers at airports and ports, who earlier checked cargo randomly, are now inspecting all consignments, leading to delays, an official from a Hyderabad-based drug company told ET. In a WhatsApp chat group of Indian drug manufacturers, several companies complained about their goods not getting cleared.\r\n<br/>\r\nThe border clash at Galwan Valley spilled over to trade between the two countries, with growing anti-China sentiment and calls to boycott Chinese products. China''s exports to India account for 2.8% of its outbound shipments.\r\n<br/>\r\n', 'healthcare2-thinkstock.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/drug-makers-urge-commerce-ministry-to-clear-stuck-imports/articleshow/76652111.cms', '2020-07-08 10:29:04'),
(59, 'Expect to launch 25 products in US this fiscal: Dr Reddy''s ', '2020-06-28', 'Dr Reddy''s Laboratories expects to launch 25 products in the US market in the current financial year, according to a top company official. The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.', 'Dr Reddy''s Laboratories expects to launch 25 products in the US market in the current financial year, according to a top company official. The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.\r\n<br/>\r\n"On a full-year basis (2019-20), we launched 27 products, including four re-launch of the earlier discontinued products. We expect the new launches momentum to continue during the year with about 25 product launches lined up despite uncertainty due to COVID-19," Dr Reddy''s Laboratories CEO Erez Israeli said in an analyst call.\r\n<br/>\r\nAs of March 31, 2020, the company has 99 cumulative filings pending for approval with the US Food and Drug Administration (USFDA), including two new drug approvals (NDAs), he added.\r\n<br/>\r\n', 'nhu1.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/expect-to-launch-25-products-in-us-this-fiscal-dr-reddys/articleshow/76672364.cms', '2020-07-08 10:32:15'),
(60, 'Bharat Biotech’s Covid vaccine gets DCGI nod for clinical trials  ', '2020-06-29', 'The SARS-CoV-2 strain was isolated in NIV and transferred to Bharat Biotech, which has developed the indigenous, inactivated vaccine at its biosafety level-3 (BSL-3) high containment facility located in Genome Valley in Hyderabad outskirts.', 'Indian vaccine manufacturer Bharat Biotech has announced obtaining the approvals of the Drug Controller General of India to initiate phase-I and II human clinical trials for the vaccine candidate for Covid-19 it developed in collaboration with the National Institute of Virology, part of the Indian Council of Medical Research.\r\n<br/>\r\nThe SARS-CoV-2 strain was isolated in NIV and transferred to Bharat Biotech, which has developed the indigenous, inactivated vaccine at its biosafety level-3 (BSL-3) high containment facility located in Genome Valley in Hyderabad outskirts.\r\n<br/>\r\nThe DCGI granted permission to Bharat Biotech to initiate human clinical trials after the Hyderabad headquartered vaccine maker submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July, said the company in a late evening statement.\r\n<br/>\r\nAnnouncing the development milestone for the first indigenous vaccine candidate Covaxin, Bharat Biotech chairman Dr Krishna Ella said, “The collaboration with ICMR and NIV was instrumental in the development of this vaccine.”\r\n<br/>\r\n', 'vaccine.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-bio-gets-dcgi-nod-for-indigenous-covid-vaccine-human-trials/articleshow/76694821.cms', '2020-07-08 10:58:14'),
(61, 'Antiviral hyped as potential Covid treatment "ineffective", finds major study', '2020-06-30', 'Lopinavir-ritonavir showed “no beneficial effect” in hospitalised patients not on ventilators, as per University of Oxford’s Recovery trial – the world’s largest randomised clinical trial of potential Covid treatments. “The data convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised Covid-19 patients,” it said.\r\n', 'An antiviral drug used to treat HIV and earmarked as a potential Covid-19 treatment is “ineffective” in treating Covid-19, a major study has indicated.\r\n<br/>\r\nLopinavir-ritonavir showed “no beneficial effect” in hospitalised patients not on ventilators, according to the University of Oxford’s Recovery trial – the world’s largest randomised clinical trial (RCT) of potential Covid-19 treatments.\r\n<br/>\r\n“The data convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised Covid-19 patients,” it said.\r\n<br/>\r\nMany countries which currently recommend the drug should revise their guidelines in the wake of the results, experts said, as they pulled the medication from the trial.\r\n<br/>', 'antiviral-hyped-as-potential-covid-treatment-ineffective-finds-major-study.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/antiviral-hyped-as-potential-covid-treatment-ineffective-finds-major-study/articleshow/76703597.cms', '2020-07-08 11:04:23'),
(62, 'Dr Reddy’s partners Fujifilm to launch Avigan for Covid-19 treatment', '2020-07-01', 'The agreement provides for Fujifilm Toyama Chemical, a unit of the Japanese company to grant Dr. Reddy''s and Dubai-based Global Response Aid the right to develop, make and sell Avigan overseas and get a lump-sum license fee and royalties on sales.', 'HYDERABAD: Indian generic drug maker Dr Reddy’s Laboratories has partnered with the Japanese pharma giant Fujifilm Toyama Chemical and Global Response Aid (GRA) for development, manufacture and sale of antiviral drug Avigan (favipiravir) tablets for potential treatment of Covid-19.\r\n<br/>\r\nThe agreement grants Dr Reddy’s exclusive rights for India and grants both Dr Reddy’s and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia.\r\n<br/>\r\nEarlier in 2011, Dr Reddy’s had formed a joint venture with Fujifilm for generic drugs business in the Japanese market but both the companies called off the venture after two years as the venture did not take off.\r\n<br/>', 'abc.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/fujifilm-to-partner-with-dr-reddys-to-sell-avigan-overseas-as-covid-19-treatment/articleshow/76727482.cms', '2020-07-08 11:26:38'),
(63, 'Pharma major Mylan gets go-ahead to make remdesivir for ''restricted emergency use''  ', '2020-07-02', 'Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted. On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.', 'NEW DELHI: After Hetero and CiplaNSE -0.34 %, another pharmaceutical major Mylan was given permission by India''s drug regulator on Thursday to manufacture and market the anti-viral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said.\r\n<br/>\r\nWritten informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted.\r\n<br/>\r\nOn June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.\r\n<br/>\r\nThe Union Health ministry in its ''Clinical Management Protocols for COVID-19'' recommended the use of the drug in COVID-19 patients with moderate stages of the illness (those on oxygen support).\r\n<br/>\r\n', 'remdesivir.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pharma-major-mylan-gets-go-ahead-to-make-remdesivir-for-restricted-emergency-use/articleshow/76750791.cms', '2020-07-08 11:36:08'),
(64, 'COVID-19 vaccine by Ahmedabad-based Zydus Cadila gets DCGI nod for human clinical trials ', '2020-07-03', 'The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, sources said.\r\n', 'NEW DELHI: After Bharat Biotech''s Covaxin, another potential COVID-19 vaccine indigenously developed by Ahmedabad-based Zydus Cadila Healthcare Ltd got nod from the Drugs Controller General of India (DCGI) on Thursday for human clinical trials, government sources said.\r\n<br/>\r\nThe approval process was fast-tracked following recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.\r\n<br/>\r\n"DCGI Dr V G Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila HealthcareNSE -0.59 % Ltd on Thursday after its animal studies was found to be successful," a official source in the know of the developments told PTI.\r\n<br/>\r\nThe assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with resp ..\r\n<br/>\r\n', 'vaccineeeee-bccl.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covid-19-vaccine-by-ahmedabad-based-zydus-cadila-gets-dcgi-nod-for-human-clinical-trials/articleshow/76762432.cms', '2020-07-08 11:39:42'),
(65, 'NIH and DBT to review vaccine candidates for Covid-19 this week', '2020-07-06', 'The meeting will see research groups and vaccine developers funded through India-US tieups present their progress on Covid-19 vaccines and discuss ways to take the development forward.\r\n', 'MUMBAI: Experts from the National Institute of Health (NIH), US, and India’s department of biotechnology will meet this week as part of a joint vaccine development programme to review the progress made on vaccine candidates for Covid-19, people aware of the development said.\r\n<br/>\r\nThe meeting will see research groups and vaccine developers funded through India-US tieups present their progress on Covid-19 vaccines and discuss ways to take the development forward.\r\n<br/>\r\nThe Indo-US Vaccine Action Program is a 35-year-old partnership between the two countries in which the NIH and DBT have come together to look at research in areas such as TB clinical research and human immunology, antimicrobial resistance, chikungunya vaccines, infant immunology and respiratory syncytial  ..\r\n<br/>\r\nThis time the meeting will focus on Covid-19 vaccines where Indian companies with US tie ups will present their research on the development of Covid-19 vaccine and their pathways.\r\n<br/>\r\nIndia’s vaccine development programme is led by the department of biotechnology which has funded five Indian companies for their work on readying a vaccine for SARS-CoV-2. Companies that have received DBT funding include Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals, Biological E and Serum Institute ..\r\n<br/>', 'test.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nih-and-dbt-to-review-vaccine-candidates-for-covid-19-this-week/articleshow/76807204.cms', '2020-07-08 11:46:36'),
(66, 'Caplin Point Labs'' subsidiary inks distribution pact with Xellia Pharma for 5 injectables in US  ', '2020-07-07', 'The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.\r\n', 'NEW DELHI: Drug firm Caplin Point Laboratories on Tuesday said its subsidiary has entered into a distribution agreement with Xellia Pharmaceuticals for five injectable products in the US. The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.\r\n<br/>\r\n"Caplin Steriles Limited (a Subsidiary of Caplin Point Laboratories Ltd) has entered into a private label distribution agreement with Xellia Pharmaceuticals for five generic injectable abbreviated new drug application (ANDA) in the US," it said.\r\n<br/>\r\nCaplin Point Laboratories Chairman C C Paarthipan said the company has partnered with Xellia which has a long standing track record of commercial success in the US for injectable products.\r\n<br/>\r\n"These ANDAs are under Caplin Steriles name and Xellia will be commercialising them in the US," he added.\r\n<br/>\r\nPeter Karas, Xellia''s Vice President Global Business Development said "Caplin Steriles'' focus on these essential medicines and their robust supply chain fits well with our track record \r\n<br/>', 'healthcare-india-getty.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/caplin-point-labs-subsidiary-inks-distribution-pact-with-xellia-pharma-for-5-injectables-in-us/articleshow/76827893.cms', '2020-07-08 11:51:48'),
(67, 'Lupin recalls diabetes treatment drug in US  ', '2020-07-08', 'Drug major Lupin Ltd on Wednesday said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release tablets in the US market.\r\n', 'Drug major LupinNSE -0.59 % Ltd on Wednesday said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release tablets in the US market. In a regulatory filing, the company said that it is voluntarily recalling its Metformin Hydrochloride extended-release tablets USP, 500 mg and 1000 mg products in the US.\r\n<br/>\r\n"This recall is being conducted out of an abundance of caution in line with the ongoing interaction with the US Food and Drug Administration on NDMA impurity levels," the filing said.\r\n<br/>\r\nLupin''s US subsidiary, Lupin Pharmaceuticals Inc, distributes Metformin Hydrochloride extended-release tablets USP in the strengths of 500 mg and 1000 mg in the US\r\n<br/>\r\n"We believe that the issues identified in the concerned products are addressable and we expect to re-introduce our updated Metformin Hydrochloride extended-release tablet product(s) in the US during the current quarter," the company said.\r\n<br/>\r\nFurther, "we wish to separately clarify that all of the company''s Metformin products manufactured and marketed in India have been tested for NDMA levels and have been assessed to be safe for patients and comply with all relevant regulatory norms," it ..\r\n<br/>', 'lupin-othersss.png', 'https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-recalls-diabetes-treatment-drug-in-us/articleshow/76848785.cms', '2020-07-08 11:55:52');

-- --------------------------------------------------------

--
-- Table structure for table `remark`
--

CREATE TABLE IF NOT EXISTS `remark` (
  `id` int(11) NOT NULL,
  `name` varchar(50) NOT NULL,
  `email` varchar(20) NOT NULL,
  `phone` varchar(20) NOT NULL,
  `description` varchar(500) NOT NULL,
  `obid` int(11) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `remark`
--

INSERT INTO `remark` (`id`, `name`, `email`, `phone`, `description`, `obid`, `createdate`) VALUES
(1, 'binjal', 'binjal308@gmail.com', '785412056', 'This is test remark.Please ignore it.', 2, '2020-02-07 13:09:57');

-- --------------------------------------------------------

--
-- Table structure for table `user`
--

CREATE TABLE IF NOT EXISTS `user` (
  `id` int(11) NOT NULL,
  `name` varchar(50) NOT NULL,
  `email` varchar(30) NOT NULL,
  `phone` varchar(20) NOT NULL,
  `password` varchar(30) NOT NULL,
  `ip_address` varchar(255) NOT NULL,
  `device` varchar(255) NOT NULL,
  `status` int(10) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `user`
--

INSERT INTO `user` (`id`, `name`, `email`, `phone`, `password`, `ip_address`, `device`, `status`, `createdate`) VALUES
(1, 'Binjal', 'binjal@gmail.com', '7485963210', '1234', '::1', '', 0, '2020-02-12 08:48:26'),
(2, 'dddd', 'bb@gmail.com', '4444444444', '1234', '::1', '', 0, '2020-03-07 10:46:00');

-- --------------------------------------------------------

--
-- Table structure for table `your_questions`
--

CREATE TABLE IF NOT EXISTS `your_questions` (
  `id` int(11) NOT NULL,
  `name` varchar(50) NOT NULL,
  `email` varchar(50) NOT NULL,
  `phone` varchar(50) NOT NULL,
  `question` varchar(255) NOT NULL,
  `remark` varchar(255) NOT NULL,
  `createdate` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `your_questions`
--

INSERT INTO `your_questions` (`id`, `name`, `email`, `phone`, `question`, `remark`, `createdate`) VALUES
(1, 'sds', 'binjal308@gmail.com', '9925509584', 'sads', 'sadsa', '2020-02-11 10:51:54'),
(2, 'sds', 'skajal1109@gmail.com', '7405592221', 'sds', 'sdsa', '2020-02-12 06:33:44');

--
-- Indexes for dumped tables
--

--
-- Indexes for table `admin`
--
ALTER TABLE `admin`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `ads_with_us`
--
ALTER TABLE `ads_with_us`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `blogs`
--
ALTER TABLE `blogs`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `case_studies`
--
ALTER TABLE `case_studies`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `category`
--
ALTER TABLE `category`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `category_subcategory`
--
ALTER TABLE `category_subcategory`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `company`
--
ALTER TABLE `company`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `current_affairs`
--
ALTER TABLE `current_affairs`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `form483`
--
ALTER TABLE `form483`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `guest_blog`
--
ALTER TABLE `guest_blog`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `inspector`
--
ALTER TABLE `inspector`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `inspector_details`
--
ALTER TABLE `inspector_details`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `news`
--
ALTER TABLE `news`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `remark`
--
ALTER TABLE `remark`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `user`
--
ALTER TABLE `user`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `your_questions`
--
ALTER TABLE `your_questions`
  ADD PRIMARY KEY (`id`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `admin`
--
ALTER TABLE `admin`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=2;
--
-- AUTO_INCREMENT for table `ads_with_us`
--
ALTER TABLE `ads_with_us`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=2;
--
-- AUTO_INCREMENT for table `blogs`
--
ALTER TABLE `blogs`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=4;
--
-- AUTO_INCREMENT for table `case_studies`
--
ALTER TABLE `case_studies`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=2;
--
-- AUTO_INCREMENT for table `category`
--
ALTER TABLE `category`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=13;
--
-- AUTO_INCREMENT for table `category_subcategory`
--
ALTER TABLE `category_subcategory`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=88;
--
-- AUTO_INCREMENT for table `company`
--
ALTER TABLE `company`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=42;
--
-- AUTO_INCREMENT for table `current_affairs`
--
ALTER TABLE `current_affairs`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=3;
--
-- AUTO_INCREMENT for table `form483`
--
ALTER TABLE `form483`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=541;
--
-- AUTO_INCREMENT for table `guest_blog`
--
ALTER TABLE `guest_blog`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=3;
--
-- AUTO_INCREMENT for table `inspector`
--
ALTER TABLE `inspector`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=60;
--
-- AUTO_INCREMENT for table `inspector_details`
--
ALTER TABLE `inspector_details`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=8;
--
-- AUTO_INCREMENT for table `news`
--
ALTER TABLE `news`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=68;
--
-- AUTO_INCREMENT for table `remark`
--
ALTER TABLE `remark`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=2;
--
-- AUTO_INCREMENT for table `user`
--
ALTER TABLE `user`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=3;
--
-- AUTO_INCREMENT for table `your_questions`
--
ALTER TABLE `your_questions`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT,AUTO_INCREMENT=3;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
